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SUMMARY
Coeliac disease is defined as a permanent gluten sensitive enteropathy. The
classical mucosal lesion is of villous atrophy, crypt hyperplasia and lymphocyte
infiltration of the epithelium. It is now generally agreed that a spectrum of mucosal
damage exists ranging from total villous atrophy to normal villous architecture with
increased numbers of intraepithelial lymphocytes (IEL). Gluten sensitivity can still
be demonstrated in this minimal lesion, with the IEL count falling on withdrawal of
gluten and rising again on gluten challenge. In the first part of this thesis I present
work validating computerised image analysis as a method for quantifying IEL in
small bowel biopsy in order to identify individuals with minimal change gluten
sensitive pathology.
Antibodies to the gliadin fraction of gluten and also to an unidentified tissue antigen
occur in coeliac disease. These antibodies are useful in the initial diagnosis of the
disease as well as in monitoring response to treatment and timing of biopsy
following oral gluten challenge. They are also used in the screening of individuals
who have a higher incidence of coeliac disease. In Chapter 4 I describe the setting
up of a recently developed assay for IgA endomysium antibody using human
umbilical cord, both for research and also for the routine NHS clinical service in
Lothian. I have also adapted this method for use in IgA deficient individuals by
measuring the IgG isotype of this antibody.
In other centres IgA endomysium has been used to identify previously undiagnosed
cases of coeliac disease in populations at high risk of developing the disease, such
as family members of coeliacs or individuals with insulin-dependent diabetes. In
Chapter 5 I describe our use of endomysium and antigliadin antibodies as
screening tools in a general hospital population, individuals with gastrointestinal
disease and those with type I diabetes. Through the course of this work I found
that a high number of patients with chronic liver disease had positive IgA
endomysium antibody assays with raised titres of IgA antigliadin antibodies without
evidence of coeliac disease on small bowel biopsy. By investigating this further I
found these individuals demonstrated an atypical pattern of fluorescence within the
smooth muscle of the umbilical vessels.
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Progress in the application of strict criteria for the diagnosis of gluten sensitivity has
been hampered by the lack of a rapid and reliable diagnostic test. Currently the
only evidence of gluten sensitivity is based on clinical and pathological effects of
gluten withdrawal and challenge, and this may take several months or years to
develop, requiring multiple invasive small bowel biopsies. For this reason rectal
challenge with gluten is being considered as a possible alternative method for
demonstrating gluten sensitivity. Currently this requires computerised image
analysis of multiple rectal biopsies. In the final part of this thesis I describe an
attempt at performing rectal gluten challenge using a wash technique with a
polyethylene glycol and electrolyte solution. This wash was performed before and
after instillation of gluten into the rectum and the fluid retrieved was analysed for
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Coeliac disease is defined as a permanent gluten sensitive enteropathy. It is now
generally agreed that the enteropathy may be expressed only as a high count of
intraepithelial lymphocyte (IEL) which rise with gluten loading and fall on a gluten free
diet. Separate studies have shown an unusual serum antibody in untreated coeliac
patients, endomysium antibody (EmA) and there are people who have positive EmA
and virtually normal biopsies. Some of these at least have however been found to
have a high count of IEL. These and other studies such as in immunogenetics are
suggesting that we may have to widen our definition of coeliac disease and gluten
sensitivity, and be more aware of the possibility of a role of gluten in patients who do
not have classical pathology. Progress in the application of strict criteria of gluten
sensitivity has been hampered by the fact that currently the only evidence is based on
clinical and pathological effects of gluten withdrawal and challenge which may take
months or years and require multiple invasive small bowel biopsies. For this reason
rectal challenge with gluten is being considered as a possible alternative method for
demonstrating gluten sensitivity. Currently, this requires computerised image analysis
of multiple rectal biopsies and is clearly not widely applicable.
Against this background my research has addressed a number of aspects relevant to
the subtle expression of gluten sensitivity, both in terms of positive serological tests
and minor pathological changes, and also subtle clinical expression which has
previously been unrecognised and can be detected in screening programmes.
My specific aims were:
1. To develop a scientifically valid method for characterising the most mild of
pathological abnormality within the spectrum of expression of coeliac disease. I
therefore set out to use computerised image analysis to obtain counts of IEL in
small bowel biopsies.
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2. An inexpensive method for detecting endomysium antibody was described
shortly after I took up my research post and I set out to develop this assay for
use in my research and also for NHS clinical service use in Edinburgh. My aim
was to further refine serological tests so that they could be applied in screening,
for example, in patients attending for Gl tests or in groups known to have a
higher than normal incidence of coeliac disease.
3. Colleagues in the Gl Laboratory already had considerable experience in the use
of a polyethylene glycol based gut lavage fluid for measuring intestinal
inflammation and immunity and I set out to establish whether a simple rectal
wash technique could be used to detect gluten sensitivity and ultimately to
investigate forms of tissue damage and immunoregulatory and inflammatory
molecules involved.
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CHAPTER 1: GENERAL INTRODUCTION
Definition and Pathology
Coeliac disease, or gluten sensitive enteropathy, can be defined as a chronic disease
in which there is a characteristic, though not specific, mucosal lesion of the small
intestine that impairs nutrient absorption by the involved bowel (picture 1.1). There is
prompt improvement of both the absorption and the mucosal lesion on withdrawal of
wheat gliadins and the equivalent barley, rye and oat prolamins from the diet (Trier,
1991) with relapse occurring on their dietary reintroduction.
Gluten sensitivity is associated with a spectrum of mucosal lesions, and it would
appear that all these lesions comprise a dynamically interrelated series of events
(Marsh and Crowe, 1995). Classically, in untreated coeliac disease the small intestinal
mucosa is flat with flattened, or cuboidal, enterocytes and hyperplastic crypts (Marsh,
1972). There is an infiltration of intraepithelial lymphocytes (IEL), which display an
increased rate of mitotic activity (Marsh, 1982).
Fry et al (1972; 1974) described marked infiltrations of intraepithelial lymphocytes
within a structurally normal mucosa in proximal small bowel biopsies from patients with
dermatitis herpetiformis (DH). These lesions improved on withdrawal of gluten from
the diet and gluten-associated IEL infiltration with otherwise normal pathological and
histological appearances is now recognised in individuals without DH. This infiltration
is also seen in the presence of crypt hyperplasia and graft-versus-host reactions in
experimental animals suggest this is a local T-cell-dependent response of the intestinal
mucosa to foreign antigen (Mowat and Ferguson, 1982). IEL infiltration probably does
not damage the mucosa as there is no evidence of structural or functional impairment.
In addition to gluten sensitivity, infiltration may occur in tropical sprue, parasitic or viral
infection, AIDS enteropathy or graft-versus-host disease (Marsh and Crowe, 1995).
There have been recent reports of high numbers of IEL occurring in the presence of
the coeliac associated endomysium antibody (Picarelli et al, 1996), and this may prove
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Picture 1.1 Classical histology of coeliac disease showing subtotal villous atrophy with
crypt hyperplasia and increased numbers of intraepithelial lymphocytes
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to be a useful tool in the diagnosis of low grade gluten sensitive enteropathy.
Genetics of Coeliac Disease
T-cells are unable to recognise antigen directly but require it to be presented bound to
a cell-surface human ieukocyte antigen (HLA) molecule on an antigen presenting cell
(APC). The HLA molecules can be divided into two classes, reflecting differences in
tissue expression, antigen processing and presenting pathways, and in T-cell receptor
(TCR) recognition. Class I molecules possess a binding site for the T-cell accessory
molecule CD8, and so tend to present antigen only to CD8+ T-cells. Class II molecules
do not interact with CD8, but do so with CD4 (Tighe and Ciclitira, 1995). The genes
encoding for components of the antigen-presenting system are located mainly on the
short arm of chromosome 6 in the region termed the major histocompatibility complex
(MHC). The class I region spans 1.5 million base pairs and includes the classical class
I loci, HLA-B, -C, and -A in addition to non-classical loci HLA-E to HLA-H and genes of
unknown function. The class II region includes the three classical HLA class II loci,
HLA-DR,-DQ and -DP as well as genes involved in antigen processing for class I
presentation. Separating these two regions is the class III region which includes
genes whose products have immunological functions eg tumour necrosis factors, heat-
shock proteins along with other loci whose functions are as yet unknown (Tighe and
Ciclitira, 1995).
In 1972 an association was found between the class I allele HLA-B8 and coeliac
disease (Stokes et al, 1972). Subsequent studies have shown this association to be
with the HLA-B8, DR3 haplotype, with a stronger relative risk ascribed to the DR3
allele than HLA-B8 (Keuning et al, 1976). In Southern Europe, where the prevalence
of the HLA-B8, -DR3 haplotype is lower than in the UK there is an association between
coeliac disease and the haplotype HLA-B18, -DR3, -DQ2, indicating that the HLA
predisposition resides within the common class II region rather than the differing class I
or III regions (Rittner et al, 1984; Coniga et al, 1992).
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Other populations within Southern Europe exhibit an association between coeliac
disease and HLA-DR7 (Albert et al. 1978; DeMarchi et al, 1983). This association only
occurs in the presence of HLA-DR5 or -DR3, and similarly no association is found with
DR-5 in the absence of -DR7. DR3 haplotypes all possess the DQ alleles DQA1*0501
DQB1*0201. DR5 haplotypes possess the DQ allele DQA1*0501 but the DQB1*0301
allele in place of DQB1*0201 whereas DR7 haplotypes lack the DQA1*0501 but do
have the DQB1*0201. A heterozygous combination of the DR5/DR7 haplotypes,
therefore contains the same DQA1*0501 DQB1*0201 alleles as the DR3 haplotype.
This allele combination is found in 98% of coeliacs in northern Europe and in 92% of
those from southern Europe and has been proposed that these DQ alleles are the
primary HLA susceptibility genes of coeliac disease (Tighe et al, 1992; Sollid et al,
1989). It is therefore proposed that the definition of coeliac disease be expanded to
include the presence of DQ2, and hopefully in the next few years this will be widely
accepted.
The work presented in this thesis studied three aspects of gluten sensitivity - the small
intestinal intraepithelial lymphocyte, endomysium antibodies and rectal gluten
challenging. It is hoped that the last of these will be of use in the diagnosis of the
minor pathology variants of coeliac disease.
Small Bowel Intraepithelial Lymphocytes
Intraepithelial lymphocytes (IEL) are interspersed between and in close contact with
the epithelial cells (picture 1.2). The nuclei are densely stained and cytoplasm pale
and featureless on light microscopy (Ferguson, 1977). Many of the lymphocytes can
be seen to cross the basement membrane between the epithelium and lamina propria,
probably in both directions. IEL are primarily situated in the basal regions of the
epithelium suggesting they are not migrating into the gut lumen from the lamina
propria. In coeliac disease markedly increased numbers of small intestinal IEL are
seen and although these fall with treatment, they rarely reach normal levels (Ferguson
and Murray, 1971). Raised IEL counts of similar magnitude have also been reported
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in tropical sprue and giardiasis (Montgomery and Shearer, 1974; Ferguson et al,
1976).
Human IEL are predominantly (over 95%) CD3+CD2+ T cells (Trejdosiewicz and
Howdle, 1995). 70-90% of IEL T cells are CD8+, suggestive of a cytotoxic/suppressor
function, the majority of the rest are CD4+ (helper) cells, with a small minority (less
than 5%) of "double negative" or CD4"CD8" cells. The CD8+ subset tend to express
CD5 at reduced density compared to peripheral lymphocytes. CD5 is important for T-B
cell interactions, suggesting that IEL T cells have little involvement with B cells. The
majority of IEL T cells are CD45RO+CD45RA", a phenotype reflecting prior contact with
antigens (Cerf-Bensussan et al, 1993).
The majority of small intestinal I EL express the a[3 form of T cell receptor, with only 1-
10% expressing the y5 form (Trejdosiewicz and Howdle, 1995). In coeliac disease
there is an increase in the abundance and percentage of y8+ IEL and 90% of these
cells are CD8" (Halstensen et al, 1989). This increase persists irrespective of dietary
gluten and is seen even in well treated patients with normal or near-normal
morphology. The tendency to high counts of y5+ IEL has also been described in latent
coeliac disease (Maki et al, 1991b), in dermatitis herpetiformis (Savilahti et al, 1992)
and in those thought to be genetically predisposed to coeliac disease (Holm et al,
1992). The significance of the increase in yS+ T cells is, as yet unclear, but they may
have an "immune surveillance" role.
The functions of IEL are not yet fully understood. Human IEL demonstrate no
spontaneous cytotoxicity towards the natural killer target K562 and only weak
cytotoxicity towards colonic tumour cell lines, but their cytotoxicity can be boosted by
incubation with phytohemaglutinin, anti-CD2 or anti-CD3 (Taunk et al, 1992; Ruthlein
et al, 1992). Cytotoxic IEL express CD2, CD3 and CD8 whereas peripheral cytotoxic
lymphocytes express CD2, CD16 and NKH1. In vivo, isolated a,p+ IEL exert a strong
cytotoxicity against targets coated with enterotoxins suggesting that they can rapidly
develop TCR mediated cytotoxicity (Cerf-Bensussan et al, 1993). IEL, therefore, may
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Picture 1.2: Normal small bowel histology with enlargement demonstrating the
appearance of IEL
well play a role in the elimination of damaged or infected enterocytes. Unseparated
human IEL synthesize IFN-y and TNF-a (Ebert, 1990). Cytokine production may play a
role in protecting the gut from bacterial and viral infection, but exaggerated secretion
of IFN-y may increase epithelial cell permeability deleteriously (Hiribarren et al, 1993).
IEL may also have a role in the development of oral tolerance to dietary antigens;
injection of murine y5+ cells abrogated oral tolerance to a soluble antigen (Fujihashi et
al, 1992).
Coeliac Disease Antibodies
The majority of foreign antigens are encountered at mucosal surfaces, and 80% of all
immunoglobulin-producing cells in humans are located in the intestinal mucosa. In
order for antibody production to occur the antigen must first be phagocytosed and
processed by antigen presenting cells (APC) such as B cells, macrophages, dendritic
cells and the intestinal epithelial cell. In addition, in the gastrointestinal tract, M cells,
which overlie the Peyer's patch, are thought to sample antigens in the gut lumen and
pass them unchanged into the lamina propria and the APCs (Mayer, 1991). The
antigenic peptides are then presented by the human leukocyte antigen (HLA) type II
molecules, products of the major histocompatibility complex (MHC), situated on the cell
surfaces. These molecules contain a peptide-binding groove where the T cell epitope
(the processed peptide of 10-20 amino acids) is situated for recognition. The HLA
class II molecule and peptide complex interact with ap+CD4+ (helper) cells. This T cell
activation signals B cells to transform into antibody producing cells (Parker, 1993;
Clark and Ledbetter, 1994).
Intestinal immunity revolves around the maturation cycle of specifically primed T and B
cells from the gut associated lymphoid tissue (GALT) via the mesenteric lymphatics
and the peripheral blood back to the intestinal lamina propria ("homing"). The Peyer's
patches switch the B cells to the IgA isotype during the maturation process (Maki,
1995).
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Serological tests, at present, do not replace the need for small bowel biopsy in the
diagnosis of coeliac disease, especially in those individuals with a strong clinical
suspicion of the disease, but they do play a major role in the monitoring of treatment
and also in screening individuals in whom there is only a slight clinical suspicion of
coeliac disease. More and more these tests are being used to screen groups of
individuals at higher risk of the disease.
Isotype-specific antigliadin antibody tests are the most widely used at present
(Troncone and Ferguson, 1991). These antibodies have frequently been found in
patients with untreated coeliac disease, but the sensitivity and specificities of the
assays vary from 30-100% (Ascher et al, 1990; Bode and Gudmand-Hoyer, 1994;
Ferreira et al, 1992; Friis and Gudmand-Hoyer, 1986; Kilander et al, 1987; McMillan et
al, 1991; Not et al, 1993; Stahlberg et al, 1986; Maki et al, 1991c). Antigliadin
antibodies may be found in other conditions as well as coeliac disease and dermatitis
herpetiformis, such as inflammatory bowel disease, cows' milk enteropathy, atopic
eczema, pemphigoid and rheumatoid arthritis (Burgin-Wolff et al, 1983; Unsworth et
al, 1983; Kieffer and barnetson, 1983; Finn et al, 1985; O'Farrelly et al, 1988) and also
in healthy individuals (Grodzinsky et al, 1990; Uibo et al, 1993; Pettersson et al, 1993).
Titres of antigliadin antibodies decline with treatment with a gluten free diet (Savilahti
et al, 1983; Kilander et al, 1987) and rise again with the reintroduction of gluten in the
diet, and may predate mucosal or clinical relapse by several months (Scott et al.1992).
High titres of IgG antigliadin antibodies persist for longer after treatment than IgA class
antibodies (Troncone and Ferguson, 1991; Kilander et al, 1987). The development of
antigliadin antibodies is independent of HLA type (Pettersson et al, 1993).
Tissue antibodies in coeliac disease were first described in 1971 in the form of the
reticulin antibody test (Seah et al, 1971). Antibodies were detected using a standard
indirect immunofluorescence method using sections of rodent kidney, liver and
stomach as antigenic substrate. A particular staining pattern was recognised in
coeliac disease and dermatitis herpetiformis (Rizzetto and Donach, 1974) which
improved the sensitivity and specificity of the assay. It was noted that in untreated
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coeliac disease reticulin antibodies were primarily of IgA class (Magalhaes et al, 1974),
and a sensitivity of 97% and specificity of 98% were claimed (Maki et al, 1984b). IgA
reticulin antibodies have been found to be reliable in the detection of occult coeliac
disease (Hallstrom, 1989; Collin et al, 1990; Unsworth and Brown, 1994) and have
been used to screen populations at increased risk of coeliac disease, for example,
insulin-dependent diabetics (Maki et al, 1984a; Collin et al, 1989), Sjogren's syndrome
(Collin et al, 1992a) and autoimmune thyroid disease (Collin et al, 1994). In selective
IgA deficiency, IgG reticulin antibodies have been found to be predictive for coeliac
disease (Collin et al, 1992b).
Serum from coeliacs also reacts with human tissue. Hallstrom (1989) showed that all
reticulin antibody-positive sera produced a strong immunofluorescent pattern with
human jejunum, liver, lung and spleen. Reticulin antibodies can, therefore be tested
for using human jejunum as the substrate, and in this case the test is called the jejunal
antibody test (Karpati et al, 1990). Chorzelski et al (1983; 1984) used monkey
oesophagus to test serum from patients with coeliac disease and dermatitis
herpetiformis and named it the endomysium antibody test. Endomysium antibody is
directed against "reticulin-like" silver-stain positive fibres in the connective tissue of the
oesophageal smooth muscle called endomysium (Kumar et al, 1987). This IgA-class
tissue antibody has gained popularity as it gives almost 100% sensitivity and specificity
in coeliac disease (Ferreira et al, 1992; Hallstrom, 1989; McMillan et al, 1991; Maki et
al, 1991c; Kapuscinska et al, 1987), but its use has been limited due to the high cost
of commercial kits. More recently, however a technique has been described to detect
endomysium antibodies using indirect immunofluorescence with fixed cryostat sections
of human umbilical cord as the antigenic substrate without a fall in its accuracy
(Ladinser et al, 1994). This has dramatically reduced the cost of the test and enabled
many more centres to use testing of endomysium antibodies as a first line
investigation in individuals with a clinical suspicion of the disease as well as individuals
at high risk of developing the disease.
In dermatitis herpetiformis, two thirds of patients will show evidence of coeliac disease
on small bowel biopsy (Fry et al, 1974), but the proportion of individuals with abnormal
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biopsies increases towards 100% if multiple specimens are taken suggesting that the
lesion is more patchy than in coeliac patients (Brow et al, 1971). If endomysium
antibody is looked for in all patients with DH on a normal diet, 65% will be positive for
the antibody. Only 86% of those with STVA have IgA class endomysium antibody and
only 11% of those with PVA (Volta et al, 1992). Chorzelski et al (1983) found that 68%
of all DH patients had IgA EmA but a higher incidence of 79% was found by the same
group in a later study (1984).
Tissue antibodies in coeliac disease and DH are gluten induced, ie they are found in
untreated patients and disappear within a year of treatment with a gluten free diet
(Maki et al, 1984b; Hallstrom, 1989). They reappear on reintroduction of a normal diet
or on the relaxation of gluten free diet and have therefore been used to predict
mucosal relapse on oral gluten challenging (Kapuscinska et al, 1987; Maki et al, 1989).
Reticulin and endomysium antibodies are directed against human "reticulin" and have
been interpreted as being the autoantibodies of coeliac disease (Karpati et al, 1990).
These antibodies have been shown to be generated against a synthetic product of
human fibroblasts (Marttinen and Maki, 1993). These molecules absorbed the IgA
antibodies responsible for reticulin and endomysium antibody positivity but not the IgA
responsible for gliadin antibody positivity.
In untreated coeliac disease there are increased numbers of IgA-, IgM- and IgG-
producing plasma cells in the jejunum. The intestinal fluid contains high levels of
antigliadin antibodies (Volta et al, 1988) but, unlike serum antigliadin antibodies, the
intestinal antibodies do not fall to normal levels on a gluten free diet (O'Mahony et al,
1991). IgA-class reticulin antibodies have also been described in jejunal fluid
(Mawhinney and Love, 1975) suggesting an intestinal origin for these antibodies. In
serum, however the reticulin or endomysium antibodies are predominantly the IgAi
subclass with a ratio of IgAi:lgA2 antibodies similar to the proportion of total serum
lgA1:lgA2 suggesting a systemic origin (Garrote et al, 1991).
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Local humoral responses can be studied by measuring antibodies in jejunal aspirate
taken at the time of jejunal biopsy by capsule or in whole gut lavage fluid (WGLF)
(O'Mahony et al, 1990; O'Mahony et al, 1991). These studies showed that IgA in
WGLF is predominantly secretory type. Elevated levels of IgA and IgM were observed
in untreated coeliac disease, and intestinal fluids contained IgA and IgM antigliadin
antibodies as well as antibodies to p-lactoglobulin and ovalbumin. Secretory IgM
antibody activity persisted despite treatment with gluten free diet and was unrelated to
the degree of enteropathy. This polyclonal upregulation of mucosal IgM responses
was defined as the "coeliac-like intestinal antibody" pattern (CIA) and may be one of
the methods used to identify individuals who may be gluten sensitive but have normal
small intestinal biopsies (potential coeliac disease).
Tissue antibodies do occasionally occur in individuals with normal small intestinal
mucosal architecture and at present the diagnosis in these individuals is uncertain.
They may, however represent individuals with latent coeliac disease, in whom the
mucosa at a later date will deteriorate and develop villous atrophy (Ferguson et al,
1993; Maki et al, 1990). Persistently raised IgA antigliadin antibodies predict the later
development of coeliac disease in only 24% of patients, and IgG antigliadin antibodies
not at all. Positive reticulin antibodies, however, predict later development of coeliac
disease in 83% of cases (Collin et al, 1993) whereas the majority of patients with or
without abdominal symptoms but persistently elevated IgA antigliadin antibody titres
probably do not have latent coeliac disease (Uibo et al, 1993). It may be argued that
individuals should be treated before the development of symptoms or malabsorption
(Arranz and Ferguson, 1993), and tissue antibody tests may provide a mechanism for
identification of these patients.
Although gliadin antibodies occur in other disorders apart from coeliac disease and
dermatitis herpetiformis and they are not limited to individuals with gene markers of
coeliac disease susceptibility (Maki et al, 1991c; Pettersson et al, 1993) they may still
play a role in the pathogenesis of coeliac disease. Gluten induces IgG-mediated
subepithelial complement activation and deposition of terminal complement
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complexes, and the deposition correlates with the number of mucosal IgG cells, the
serum levels of gluten-specific IgG and IgM antibodies and the degree of villous
atrophy (Halstensen et al, 1992). Gluten, therefore, may damage the surface
epithelium in coeliac disease via immunoglobulin-mediated subepithelial complement
activation. Gliadin antibody could also cause mucosal damage via cell-mediated
cytotoxicity in which the antibody recognises gliadin peptides bound to the mucosal
structures (Unsworth et al, 1987) and directs an antibody-dependent cell-mediated
cytotoxic reaction.
Reticulin or endomysium antibodies may represent an autoantibody responsible for
initiating and perpetuating the intestinal damage seen in coeliac disease. Family
studies have shown the HLA class II molecule DQ to be the restriction element for
these antibodies (Maki et al, 1991a). Maki et al (1991a) have based their hypothesis
for coeliac disease being an autoimmune disease on the identification of self-peptides
which trigger the production of reticulin and endomysium antibodies. This hypothesis
depends on three crucial elements; the trigger (gliadin), the susceptibility MHC class II
genes (DQA/DQB) and the autoantigen. Specific HLA class II molecules on APC may
present self-peptides, thus activating the autoreactive T-cell population. The disease
is self-perpetuating if the trigger is not removed. The exact nature of the self-peptides
are yet to be determined, but may be fibroblast-derived extracellular matrix proteins
(Marttinen and Maki, 1993). A reported case of coeliac disease and
hypogammaglobulinaemia (Webster et al. 1981), however, suggests that humoral
immunity is not crucial for the development of the mucosal lesion.
Although the humoral immune system has been implicated in the development of
coeliac disease (Brandtzaeg et al.1993), it may be secondary to T-cell activation and
helper-cell recruitment. Humoral responses may be important in amplifying the
immune response and proliferation of the mucosal damage. The development of
tissue antibodies may represent the consequence of T-cell mediated damage,
exposing the self-peptides and allowing the development of autoantibodies (Marsh et
al, 1993). The lower prevalence of IgA endomysium antibodies in patients with DH
may be due to the more limited extent of bowel damage occurring in DH and this,
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therefore supports the theory that endomysium antibodies are a consequence of cell
mediated bowel damage rather than being responsible for initiating the mucosal lesion.
Rectal Gluten Challenging
Direct instillation of gluten into the ileal lumen in coeliacs induces rapid deterioration in
the mucosal architecture and it has been postulated that the rapid breakdown of gluten
in the proximal small intestine produces relative sparing of the distal small intestine
and that a similar mechanism may protect the colon (Flick et al, 1962). The same
group found abnormalities in rectal biopsies from 5% of coeliac patients namely,
increased tortuosity of the glands with branching and crypt abscesses and frequent
polymorphonuclear lymphocytes within the lamina propria (1962). The surface
epithelium was disorganised in appearance and in some patients was partially
denuded. Ensari et al (1993) found significant increases in CD3+ and y5+ lymphocytes
within the lamina propria and epithelium of untreated patients compared with treated
coeliacs but neutrophils (CD15+) were not prominent. Activated (CD25+) lymphocytes
expressing IL-2 receptors were increased in the lamina propria, but few IL-2R+ IEL
were found. The absence of neutrophils suggests this is not a conventional
inflammatory proctitis, but a cell mediated response to gluten antigens present in the
faecal stream.
A small group of coeliac patients given wheat enemas with rectal biopsies before and
at 4, 8 and 24 hours developed histological, sigmoidoscopic and clinical reactions
(Dobbins and Rubin, 1964). Erythema, maximal at 8 hours was seen on
sigmoidoscopy. Histologically, polymorphonuclear infiltration of the epithelium, lamina
propria and submucosa occurred and surface goblet cells were discharged. These
changes were maximal at 8 hours and resolving at 24 hours. Two of the four coeliac
patients developed clinical responses to the wheat enemas consisting of anorexia,
nausea, vomiting, borborygmi, loose stools and headache. Corn enemas produced no
reaction in the coeliac group, and the control group did not respond to either enema.
The biopsies taken in this study were later reviewed (Austin and Dobbins, 1988) and
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IEL counted. The IEL count of the baseline biopsies was significantly higher in the
coeliac group than in the controls and the wheat enemas induced a significant
increase in IEL in the coeliac group, maximal at 8 hours which was not seen with corn
enemas. In the control group an increase in IEL was also seen in response to wheat,
but was not significant until 24 hours.
Loft et al (1989; 1990) used a peptic-tryptic digest of gluten to challenge a group of
coeliacs and took biopsies from the rectum at frequent intervals over a four day period.
Electron microscopy was used to examine lamina propria mast cells and computerised
image analysis to quantify volumes of surface epithelium, crypt epithelium and lamina
propria along with intraepithelial lymphocytes. The gluten digest induced significant
lamina propria oedema which was biphasic in its time-course, infiltration of the lamina
propria with lymphocytes and an increase in IEL compared to controls. Histological
changes could be seen up to 96 hours after challenge. No response was seen to
rectal challenge with p-lactoglobulin. The authors used an IEL response 6 hours after
challenge of 10% or more to predict coeliac disease with sensitivity and specificity of
approximately 90%. Immunohistochemical examination of the CD3+ and y5+
populations within the mucosa may be even more sensitive (Marsh et al, 1993).
Sturgess et al (1993) found a marked rise in CD3+ IEL without significant change in the
y8+ IEL in the early response to rectal gluten challenge suggesting that a.p+ IEL are
involved in the acute mucosal response to local gluten challenge.
Rectal challenging may prove to be a useful tool in the diagnosis of coeliac disease,
especially in those individuals who do not present classically. De Sousa et al (1988),
however failed to show any response to rectal gluten challenge in a group of children
with untreated coeliac disease. In this study gluten enemas were given daily for eight
days with biopsies taken at baseline and at the end of the challenge period.
Measurements were made of total mucosal thickness, IEL counts, goblet to epithelial
cell ratio, mitotic crypt cell activity and the degree of lamina propria cellular infiltration.
The only measurement significantly different after gluten challenge was total mucosal
thickness. The different challenging protocol in this study may account for the
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absence of histological response of the rectal mucosa to gluten and highlights the
need for a robust and reproducible method for rectal gluten challenging in order for it
to be useful in routine clinical practice.
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CHAPTER 2: STANDARD METHODS
The standard laboratory methods used in my work are described in brief in this
section. Full laboratory protocols are presented in the Appendix.
Haematoxylin and Eosin Staining
The haematoxylin and eosin dye staining method is widely used in most
histopathology laboratories as in most cases it enables a diagnostic decision to be
made without the need for further specialised staining. Haematoxylin is acidophilic
and so stains the acidic nuclei a blue-black colour, and eosin acts as a counterstain
staining the cytoplasm and connective tissue various shades of pink, orange and red.
Haematoxylin itself does not stain the tissue, it must first be oxidised to haematein.
This can be done naturally, by exposing the haematoxylin to light and air, but the
process can take several months. Alternatively chemical oxidation using sodium
iodate or mercuric oxide can be employed, and the dye is ready for use immediately.
Haematein alone has poor affinity for tissue and so requires a mordant in order to bind
to the section, and aluminium is used for this purpose in our laboratory. This stains
the nuclei red initially, but changes to blue on washing with weak alkali. Eosins are
xanthene dyes, and the most widely employed is eosin Y.
For staining, the sections are initially dewaxed in Histoclear and then hydrated through
graded alcohol (absolute alcohol and then 70% alcohol) and tap water. They are then
stained in alum-haematoxylin for 10 minutes followed by a 10 minute wash in tap
water, which turns the staining blue. This blue staining of the connective tissues and
cytoplasm is then removed by immersing in 70% alcohol. The sections are washed
again in tap water and then saturated lithium carbonate to return the nuclear staining
to blue. They are then counterstained in eosin for five minutes before a further wash
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in tap water. Further dehydration through graded alcohols is then performed before a
final immersion in histoclear and coverslipping in DPX.
Quantifying IEL in Small Intestinal Biopsies using Light Microscopy
IEL are usually increased in the small intestinal biopsies of patients with untreated
coeliac disease or dermatitis herpetiformis. These cells can be demonstrated by
haematoxylin and eosin staining, and in well orientated 3pm paraffin wax sections can
be quantified when examined under the light microscope.
The microscope is set to give optimal resolution and even illumination by using Kohler
illumination. The small bowel biopsy sections are examined using oil immersion and a
x100 objective . Beginning at one edge of the slide and the bottom of a villus the
epithelial cell nuclei and intraepithelial lymphocytes are counted. Lymphocytes
straddling the basement membrane are included, but unidentifiable nuclear fragments
are ignored. Areas of poor orientation or where the lamina propria has shrunk from
the cell border are not counted, nor are goblet cells or crypt epithelial cells. In poorly
orientated or small sections it is possible to count transversely cut villi, but a count may
prove impossible in total villous atrophy. Cells are counted until 500 epithelial cells are
reached and the IEL count expressed per 100 surface enterocyes. The normal range
is 10-40 IEL per 100 surface enterocytes.
Staining of CD3+ and y5+ Lymphocytes in Small Bowel Biopsy
The staining of these lymphocytes was performed by Mr John Bode. CD3+ and y5+
lymphocytes are increased in the small intestinal epithelium of patients with coeliac
disease. These cells can be detected by immunocytochemistry using the monoclonal
antibodies, anti-CD3 and anti-y8 on frozen biopsy sections enabling detection by
microscopy.
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Small bowel biopsies are orientated on embedding compound using a dissecting
microscope prior to quick-freezing with Cryospray (Bright Instument Co, UK). They are
then stored at -70°C until sectioning on a cryostat. 6pm sections are allowed to dry
before fixing in acetone.
Fixed sections are incubated with normal rabbit serum (Scottish Antibody Production
Unit (SAPU), Scotland) to block any non specific antibody interaction. Mouse anti-CD3
or anti-y5 (both SAPU) is then applied and incubated for one hour. The sections are
washed before biotinylated rabbit anti mouse IgG (Dako Ltd, Denmark) is applied for a
further hour and then washed off. Steptavidin/biodin peroxidase complex is then
applied for another hour before rinsing. The sections are then treated with DAB before
further washing with tap water. Haematoxylin is then applied, washed and lithium
carbonate applied until the sections turn blue. They are then washed in tap water,
70% alcohol, absolute alcohol, isopropronal and histoclear before mounting in DPX.
Computerised Image Analysis
Image analysis is a method of making geometric and densitometric measurements on
images from any source. Its main application is in quantitative microscopy, replacing
traditional subjective measurements. The image analyser (Leica Q500MC, Leica,
Germany) uses a television camera to sample an image from the microscope. The
camera generates an electronic signal proportional to the intensity of illumination which
is then digitalised into picture elements or "pixels". At each pixel the brightness of the
image is sampled and this digital representation is analysed by the personal computer
attached to the system.
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CD3+ and y5+ IEL Counts in Small Bowel biopsies
The surface of the epithelium is traced using the mouse and the stained cells marked
and counted by the computer. Cumulative counts of several fields have been
performed for each stain and the results shown in figures 2.1 and 2.2. It can be seen
that for the CD3+ counts ten fields should be counted to ensure an accurate
measurement, but the y5+ cell counts require 20 fields to reduce variability in the count.
Antigliadin Antibody ELISA
This assay was performed by Mr John Bode. IgA- and IgG-class antigliadin antibodies
are measured by a sandwich ELISA technique. Flat bottomed, gamma irradiated 96
well plates (Immulon 2, Dynatech Laboratories Inc, USA) are coated with a 25pg/ml
gliadin solution (G-3375, Sigma Chemical Co, UK) before incubating at 22°C for five
hours. The plates are washed three times before blocking with ELISA diluent (0.9%
saline, 0.05% Tween 20 and 1% adult bovine serum) for two hours. Human standards
and samples are diluted to 1/100 for IgA and 1/200 for IgG using diluent and added to
the plates. The standard is applied in duplicate with doubling dilutions, and the
samples are applied in duplicate in a single dilution. The plates are incubated
overnight at 4°C in a moist, covered box. After further washing, alkaline phosphatase
conjugated anti-human sera are applied before a further incubation at 22°C for five
hours. Alkaline phosphatase substrate (Sigma) is applied after further washing and
the colour allowed to develop. The plates are read using a Dynatech Microplate
Reader using the top standard optical density of 1.00 as an endpoint. A standard
curve is plotted and the sample values calculated from this.
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Figure 2.1: Cumulative CD3+ cell count plotted against number of fields counted
6-i
Field
Figure 2.2: Cumulative y8+ cell count plotted against number of fields
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Whole Gut Lavage Fluid Collection
The technique for performing whole gut lavage used in our department was developed
by my predecessor, Dr Seamus O'Mahony. The technique is based on that described
by Gaspari et al (1988), which in turn is adapted from a method originally developed
for use in the mouse (Elson et al, 1984).
The solution used for the lavage procedure is a polyethylene glycol (PEG) based
electrolyte solution. Commercially this is available as "Klean-Prep" or "Movicol"
(Norgine, UK), and is widely used as a bowel preparation for barium enema or
colonoscopy (DiPalma et al, 1984), and also for the treatment of severe constipation
(Puxty and Fox, 1986; Logan et al, 1978). The commercial preparations are in the
form of a sachet of powder which is mixed into one litre of water in order to make the
solution.
Following an overnight fast, the lavage procedure begins at 8.30 am. The individual
drinks the lavage solution at a rate of 250mls every 15 minutes until the material
passed per rectum is a clear liquid, free of faecal material. Most individuals require
approximately four litres to achieve this result. 200mls of this effluent are collected to
be processed and aliquotted.
Whole Gut Lavage Fluid Processing and Storage
Initially, three 1.5ml aliquots of the raw fluid are taken and 6mg sodium azide added as
a bactericidal agent. These tubes are labelled "unfiltered/unprocessed". 10ml of
lavage fluid is filtered through a glass fibre filter (Whatman GF/A 12.5 filter paper).
5ml each of filtered and raw, unfiltered fluid are placed in separate tubes. To each is
added, 500mg soya bean trypsin inhibitor (SBTI), 280pl 0.3M disodium ethylene
diamine tetra-acetic acid (EDTA), 120pil of 0.3M PMSF (phenylmethylsulphonylfluoride)
all of which act as protease inhibitors, and 12mg of sodium azide. The tubes are
23
allowed to stand for two minutes prior to the addition of 300pl newborn calf serum
which provides an alternative substrate for any remaining protease (Elson et al, 1984).
The fluid is then dispensed into microcentrifuge tubes and labelled "filtered/processed"
and "unfiltered/processed" respectively. The tubes are stored at -70°C prior to
analysis.
Assay Techniques for PEG Based Rectal Wash Fluid
Albumin and Alpha-1 -Antitrypsin
These assays were performed by Mr John Bode. When human albumin and a-1-
antitrypsin react with their specific antibodies in the presence of polyethylene glycol,
precipitating immune complexes form. In the presence of excess antibody these
precipitates produce turbidity which can be photometrically measured at wavelength
340nm. This principle was used to measure the amounts of albumin and a-1-
antitrypsin in the rectal wash fluid. Absorbance readings obtained by measuring
calibration standards were used to generate a standard curve from which the
concentration of albumin or a-1-antitrypsin in the sample was derived (Brydon et al,
1993).
These assays were performed on filtered/processed specimens using SPS01 (Protein
Reference Unit, Sheffield) as the calibration standard with sheep anti-human albumin
and goat anti-human a-1-antitrypsin antibodies respectively. A quality control of gut
lavage from a normal volunteer was used in which serum from the same volunteer was
added to stimulate gut protein leakage and the results accepted when the quality
control value was +/- 22% of the expected value. The results are expressed as ^g of
albumin or a-1-antitrypsin per ml of fluid.
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Haemoglobin
This assay was performed by Mr John Bode. Haemoglobin was converted to
fluorescing porphyrins by the removal of iron. Total haemoglobin was determined by
reaction with heated oxalic acid:FeS04 reagent which converts haem to porphyrin
without loss of preformed porphyrins. Fluorescence was measured using a
luminescence spectrometer.
The analysis was performed on unfiltered/unprocessed material and the process of
freezing causes haemolysis of any intact red blood cells allowing accurate
measurement of total haemoglobin. Once thawed the samples were centrifuged to
remove cell debris and the supernatant used.
Once the haemoglobin had reacted with the oxalic acid reagent a three step
purification procedure was performed. The porphyrin analytes were extracted into an
upper organic phase by adding potassium acetate and ethyl acetate/acetic acid.
Butanol and potassium acetate in potassium hydroxide were then added to the organic
phase in order to remove coproporphyrin and other porphyrins not derived from
haemoglobin into a lower alkaline aqueous phase. Phosphoric acid/acetic acid was
then added to the organic phase and the fluorescence of the lower acid extract was
measured.
Cyanomethaemoglobin (Haemoglobin (Sigma Chemical Co Ltd, Uk) dissolved in
Drabkin's reagent) was used as the standard and haemoglobin dissolved in Klean-
Prep was used as the quality control. The coefficient of variation of the quality control
material is currently 8%. The results were accepted if the quality control value fell
within two standard deviations of the mean value of the quality control. Results are
expressed is pg of haemoglobin per ml of fluid.
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Total Immunoglobulins
These assays were performed by myself and Mr Kenneth Humphreys. Class A, G and
M immunoglobulins were measured by ELISA. 96 well plates (Immulon 1, Dynatech
Laboratories Inc., USA) were coated with goat anti-human IgA, G or M and incubated
at 4°C overnight. The plates were washed three times before blocking with ELISA
diluent and incubating at room temperature for one hour. Standard material (SPS01
for IgG and IgM, colostrum for IgA) and filtered/processed samples were applied in
doubling dilutions and the plates again incubated at 4°C overnight. The plates were
washed three times before alkaline phosphatase conjugated goat anti-human IgA, G
or M was applied. Following a three hour incubation period the plates were again
washed and developing solution applied. The optical density of each well was then
measured and a standard curve plotted.
The results were accepted if the correlation coefficient of the linear portion of the
standard curve was > 0.985 and two points of the sample curves were parallel to the
standard curve. Results are expressed as pg of immunoglobulin per ml of fluid.
Cytokines
These assays were performed by Dr Andrea Lear and Mrs Hazel Drummond. IL-ip,
IL-6, IL-8 and TNF-a were assayed using commercial ELISA kits (R&D Systems,
Eurogenetics and Cistron Biotechnology). Each kit used a quantitative sandwich
ELISA technique. The plates were coated with a monoclonal antibody specific to the
cytokine of interest. Samples and standards were pipetted into the wells and the
cytokine bound by the immobilizing antibody. Unbound proteins were then washed
away and an enzyme-linked polyclonal antibody specific to the cytokine applied.
Following a further wash, a substrate solution was added to the wells and colour
developed in proportion to the amount of bound cytokine. The colour intensity was
then measured.
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A standard curve was plotted and the sample values read off giving a concentration of
cytokine (pg/ml of sample). Both filtered/processed and unfiltered/processed samples
were used to assess whether filtration removed the cytokines from the samples.
Estimation of PEG concentration
This assay was performed by myself. Levels of PEG 3350 in the rectal wash fluid
were measured by the method of Malawer et al (1967), a modification of the
turbidimetric method of Hyden (1955). PEG 3350 was used as the standard and
water as the blank. Filtered/processed samples were diluted to 1:10 with water before
the addition to all the flasks of: Distilled water, BaCI2, Ba(OH)2 and ZnS04 with mixing
between each stage. After standing for ten minutes the contents were filtered through
double thickness filter paper (Whatman No 42).
1ml of filtrate was then added to 3ml of gum acacia and 4ml of 30% (w/v)
trichloroacetic acid containing 5% (w/v) BaCI2. The tubes were mixed and allowed to
stand for one hour before the optical densities of the samples, standards and blanks
were read using a spectrophotometer (Pye Unicam PU 8610) set at wavelength 650
nm. A standard curve was constructed and the samples extrapolated from this.
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CHAPTER 3: USING COMPUTERISED IMAGE ANALYSIS TO QUANTIFY SMALL
INTESTINAL INTRAEPITHELIAL LYMPHOCYTES
Introduction
Intraepithelial lymphocytes (IEL) have previously been quantified in small bowel
biopsies by several different techniques. Ferguson and Murray (1971) described a
differential count of the nuclei of the epithelial layer seen under light microscopy.
Formalin fixed, paraffin embedded jejunal sections stained with haematoxylin and
eosin (H+E) were used. The epithelium was examined under a high power objective
enabling the nuclei of epithelial cells, lymphocytes and goblet cells to be distinguished
and counted. Only well orientated areas of surface epithelium were used and small
unclassifiable nuclear fragments were discounted. Goblet cell nuclei were not
included, nor were intraepithelial eosinophils or lymphocytes in transit across the basal
lamina. For each specimen a total of 500 epithelial cell nuclei were counted and the
IEL count expressed as cells per 100 epithelial cells. The normal range using this
technique was calculated to be 6-40 IEL per 100 villus epithelial cells.
An alternative method used a graticule within the eye piece of the microscope. This
enabled a given length or area of epithelium to be examined. Formalin fixed, paraffin
embedded sections were again used, and stained with H+E. Holmes et al (1974)
examined 1660pm of epithelium and counted the nuclei of IEL contained within it. The
count was expressed as IEL per mm epithelium. R Ferguson and colleagues (1974;
1975) used the graticule to divide the histological field into squares and nuclei within
50 squares of epithelium were counted and the total count converted into number of
cells per mm2 using a conversion factor. These techniques all showed an increase in
the number of IEL in the small bowel biopsies of patients with coeliac disease and
dermatitis herpetiformis.
Guix et al (1979) again used an eyepiece graticule, but this time measured a unit
length of muscularis mucosa and from this calculated the epithelial surface area as
well as the volume of the lamina propria. The IEL were counted in epithelium (villi and
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crypts) related to the unit length of muscularis mucosa. In this case the count was
given in absolute figures. This method showed no significant difference between IEL
counts in coeliac and non-coeliac individuals, suggesting that the total number of IEL
does not increase in coeliac disease, but reduction in the epithelial volume leads to an
increase in the ratio of IEL to epithelial cells.
Increasingly, mild degrees of gluten sensitive enteropathy are being recognised with a
raised number of IEL per 100 epithelial cells as the only abnormality. In view of the
importance for my work of assigning patients to normal or abnormal groups with
respect to mucosal infiltration by IEL, and as the ideal method for quantifying these
cells would be by computerised image analysis, I decided to concentrate on IEL per
unit length of mucosal epithelium.
Development of the Computerised Technique and Comparison with Light
Microscopy
IEL were counted in 3^im sections of formalin fixed, paraffin embedded, H+E stained
small bowel biopsies. These were either jejunal biopsies taken by Watson capsule
under radiological control, or endoscopic distal duodenal biopsies, and the processing
and staining of the sections were performed in the Hospital Pathology department.
Further cutting and staining of sections was performed by John Bode, MLSO.
31 sections were analysed by computerised image analysis (Leica Q500MC described
in Chapter 2 and x40 objective). Fields containing well orientated lengths of epithelium
were chosen. Using the computer's mouse a line was drawn along the surface of the
epithelium, following the contours as closely as possible. The computer is able to
detect cells using pixel colour and I did hope it would be possible to exploit this facility
in order to automatically detect the IEL. Unfortunately it proved impossible to set limits
for pixel configuration and colour which were both sensitive and specific for IEL. I
found that the nuclei of goblet cells exhibited almost identical colour staining and so
were included in the count, and it also proved impossible to exclude the lamina propria
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from the field, and so lamina propria lymphocytes were automatically detected too. In
view of this I chose to manually select cells simply by "clicking" on them. The
computer counted the selected cells in each field and kept a cumulative cell count for
each biopsy. At the end of the count the computer then calculated an overall cell
count expressed as IEL per millimetre of epithelium (lEL/mm).
Initially the number of fields required for an accurate IEL count was validated using five
biopsies. Twenty fields (mean length of epithelium = 0.199mm) were analysed and
cumulative count per millimetre of epithelium was plotted against number of fields
analysed (figure 3.1). After eight fields the count plateaued and additional fields did
not alter the count. Ten fields were used as a standard for further counts.
In our laboratory, IEL have previously been counted by light microscopy using the
technique described by Ferguson and Murray (1971). This technique was therefore
used as a standard comparison for the new computerised method. The same 31
sections were analysed by light microscopy (the method is described in detail in
Chapter 2). Well orientated areas of epithelium were chosen and the nuclei of both
IEL and epithelial cells counted (IEL per 100 epithelial cells).
Counts using the two techniques were compared (figure 3.2) and linear regression
performed (1^=0.964, p<0.0001). By extrapolation from this graph, and since a value
of <40 IEL per 100 enterocytes has been the accepted reference range for light
microscopy for 20 years, an interim upper normal limit of <53/mm was calculated. As
high counts of IEL are of interest in gluten sensitivity I only defined the upper limit of
the reference range, but if ever work on immune deficiency was carried out a separate
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Figure 3.2: Comparison of IEL counts in small bowel biopsies using light microscopy
and computerised image analysis.
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Interbiopsy and Intrabiopsy Variability in IEL Count
I was concerned about the possibility of variability in the cell count depending on the
site from which the biopsy was taken. In order to assess this variability counts were
perfomed on archive material which had been collected over ten years earlier and
stored. These were multiple jejunal biopsies taken using a multiple biopsy capsule.
Two biopsies from each of nine patients were assessed. I also measured IEL in
multiple sections taken from a single large jejunal biopsy to assess intra-biopsy
variability. Three sections 100pm apart were used.
The results from the multiple biopsies are shown in table 3.1. The variability was not
significant when analysed by the Wilcoxon Signed Rank test. The IEL counts from
three sections taken from the same biopsy were 31.8/mm, 32.2/mm and 34.3/mm,
therefore showing little variability.










Table 3.1: Counts of two biopsies taken from each of nine patients using a multiple




For this technique to prove useful in a clinical laboratory setting it should not vary
when used by different observers. In order to assess the inter-observer variability
eight biopsies were examined by myself and Mr John Bode and the counts obtained
are shown in table 3.2. There was no significant difference between observers when
tested using the Wilcoxon signed rank test.









Table 3.2: IEL counts in eight small bowel biopsies performed by two independent
observers
IEL Counts in Different Diagnostic Groups
In order to assess the differences in IEL counts in different disease states I counted
IEL in small bowel biopsies from 82 patients in whom a gastrointestinal cause for their
symptoms had been identified. These patients were divided into five diagnostic
groups which are shown in table 3.3. The IEL counts are shown in figure 3.3 and were
analysed by two sample T test.
There are significant differences between counts from coeliacs on normal diet and
those on a gluten free diet (p=0.021), those with inflammatory bowel disease
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(p=0.0052), those with irritable bowel syndrome (p=0.0094) and those with bile salt
malabsorption (p=0.013).
There were also significant differences between the coeliac (gluten free diet) group
and the IBD group (p=0.019) and the IBS group (p=0.020). The difference between
the gluten free diet and bile salt malabsorption groups is not significant (p=0.11).
Patients with a final diagnosis of irritable bowel syndrome or bile salt malabsorption
would be anticipated to have normal gut immunity and so can be used to assess the
accuracy of the interim normal upper limit of up to 53 lEL/mm epithelium. It can be
seen from figure 3.3 that counts in these groups generally fall below 50/mm whereas
untreated and many of the treated coeliacs have counts greater than this value. An
upper limit of 50 cells/mm was therefore used as a reference range.
Disease Group C-ND C-GFD IBD IBS BSM
Mean age (years) 38.9 38.9 39.3 34.0 46.3
No of biopsies 13 15 7 20 28
Mean IEL count (per mm) 71.5 37.1 22.3 25.4 28.8
Standard Deviation 21.4 15.2 10.5 10.8 12.9
SEM 9.6 4.1 5.0 2.1 2.9
Range 44-124 16-66 13-43 10-35 9-59
Table 3.3: Disease groups in which IEL counts performed.
C-ND = coeliac on normal diet, C-GFD = coeliac on gluten free diet, IBD =
inflammatory bowel disease, IBS = irritable bowel syndrome, BSM = bile salt
malabsorption, SEM = standard error of the mean
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Conclusion
Using computerised image analysis to quantify IEL compares well to counting IEL by
light microscopy and relating the total to the number of epithlelial cells. There is little
variation within a single small bowel biopsy and also between biopsies taken from
different sites within the upper small bowel. In addition, the technique is not operator
dependent. In conclusion, therefore, computerised image analysis provides a reliable




















Figure 3.3: IEL counts on 82 biopsies from patients with various gastrointestinal
diseases. C-ND = Coeliac on normal diet, C-GFD = Coeliac on gluten free diet, IBD =
inflammatory bowel disease, IBS = irritable bowel syndrome, BSM = bile salt
malabsorption. Horizontal line marks the interim normal reference range
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IEL counts in biopsies with normal villous morphology
Pathology reports now often comment on the numbers of intraepithelial lymphocytes
present in small bowel biopsies. Usually this is a subjective observation rather than a
formal count of the cells. I looked at 34 biopsies with normal villous morphology in
which the pathologist felt the IEL count was raised and 216 biopsies which were
reported as being entirely normal.
In the normal group twelve patients had IEL counts of 50/mm or greater, but the
remainder had counts within the normal range. In the group reported as showing
increased IEL, 18 had counts of 50/mm or greater and 16 had normal counts. This
suggests, therefore, that the subjective assessment of IEL counts is very difficult and
inaccurate, and that in our hospital increased numbers of IEL are probably over
reported. This highlights the importance of a formal, objective measurement,
especially in those biopsies felt to have high numbers of IEL.
In view of the possibility of raised IEL counts representing low grade pathology gluten
sensitive enteropathy, symptomatic patients seen in our gastrointestinal clinic have
been offered a trial of gluten free diet to see if an improvement in symptoms could be
obtained. In our group of 30 patients with normal morphology but increased IEL,
seven were individuals with coeliac disease on gluten free diet and the details of the
remaining 23 patients are listed in table 3.4.
The response of the first eight patients would suggest that these cases were indeed
low grade pathology coeliacs, and this confirms the findings of my predecessor, Dr
Eduardo Arranz. The patient who did not respond to the diet and those in whom
symptoms were self-limiting may well have been cases of gastrointestinal infection.
Ultimately these are the cases in which additional information, such as the presence of
antiendomysium antibodies will be vital and where rectal gluten challenge could be
useful.
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Patient Symptoms lEL/mm Treatment and Outcome
LM Iron deficiency anaemia 64 GFD - anaemia now resolved
RM Diarrhoea 62 GFD - diarrhoea resolved
KT Diarrhoea 56 GFD - dairrhoea resolved
VC Diarrhoea, lethargy 56 GFD - symptoms resolved
GF Diarrhoea 52 GFD - diarrhoea resolved
KM Diarrhoea 58 GFD - diarrhoea resolved
MB Iron deficiency anaemia 50 GFD - anaemia resolved
FA Diarrhoea 52 GFD - diarrhoea resolved
CR Diarrhoea 52 GFD - no improvement
MB Diarrhoea 54 Refused GFD
AJ Iron deficiency anaemia 66 Refused GFD, given iron
JT Folate deficiency 52 Refused GFD, oral folic acid
DR Iron deficiency anaemia 54 Oral iron, not offered GFD
EM Diarrhoea 52 Self-limiting
CP Diarrhoea 72 Self-limiting
PT Diarrhoea 63 Self-limiting
DM Diarrhoea 53 Self-limiting
FM Diarrhoea 53 Self-limiting
AJ Weight loss 65 Self-limiting
NR Diarrhoea 60 Self-limiting
JB Diarrhoea 55 Self-limiting
BK Diarrhoea 50 Bacterial colonisation -
improvement with antibiotics
MG Diarrhoea 59 Cholestyramine for bile salt
malabsorption
Table 3.4: Clinical details of 23 patients with normal villous morphology and raised IEL
counts
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CHAPTER 4: IgA ENDOMYSIUM ANTIBODY MEASUREMENT
Introduction
IgA endomysium antibodies were first described in coeliac disease and dermatitis
herpetiformis by Chorzelski et al (1983; 1984). They found that serum from these
patients produced a fluorescent pattern within the smooth muscle of distal oesophagus
from monkey when an anti-human FITC labelled antibody was applied. Similar
fluorescence is also seen if human oesophagus is used (Uibo et al, 1995). Recently a
new technique has been described replacing the oesophagus with human umbilical
cord and examining for fluorescence within the smooth muscle of the cord vessel walls
(Ladinser et al, 1994).
As I have previously mentioned, IgA endomysium antibodies demonstrate almost
100% sensitivity and specificity for coeliac disease. The sensitivity in dermatitis
herpetiformis, however is much less, only 65% of patients with DH who are taking a
normal diet will demonstrate this antibody (Volta et al, 1992). Nevertheless, the
greater accuracy of this antibody over antigliadin antibodies has great potential within
routine clinical practice. Antibody measurement provides a minimally invasive first line
investigation for patients presenting with gastrointestinal symptoms which may be due
to coeliac disease, whereas small intestinal biopsy, either by capsule or endoscopy is
both invasive and time-consuming. These factors often lead to biopsy being offered
late in the line of investigation after many other, sometimes more invasive
investigations have failed to elicit a cause for the patient's symptoms.
Antibody measurement also offer an excellent means of screening individuals at high
risk of coeliac disease, for example those with type I diabetes, Down's Syndrome or
first degree relatives of coeliacs. Often these individuals are asymptomatic or have
mild symptoms that are ignored both by the individual or health professionals. Despite
this, however, evidence of malabsorption may be detected (Maki et al, 1984a; Page et
al, 1994; Sategna-Guidetti et al, 1994). In patients with symptoms from coeliac
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disease it is known that many complications can develop if the diagnosis or treatment
are delayed, or if treatment is incomplete (Holmes, 1996; Wright, 1995) but it is
unclear if asymptomatic individuals are also at risk of these complications. Screening
individuals at high risk of coeliac disease, therefore offers not only the opportunity to
correct nutritional deficiencies before symptoms develop, but will also provide vital
information as to the natural history of this group of patients.
As stated in the general introduction to this thesis, the antigen against which
endomysium antibodies are directed is, as yet, unidentified. It is also unclear as to
whether the antibody is generated in the intestinal mucosa or peripherally. Antigliadin
and antireticulin antibodies have been found in intestinal secretions (Volta et al, 1988;
O'Mahony et al, 1991; Mawhinney and Love, 1975) and so we were interested to
examine whole gut lavage fluid for endomysium antibodies, as their presence would
support mucosal production. For these reasons we were interested in developing the
IgA endomysium antibody assay in Edinburgh, for both Health Service and research
use.
It is of course important to remember that selective IgA deficiency is associated with
coeliac disease (Collin et al, 1992b; Crabbe and Heremans, 1967; Beutner et al, 1989;
Mawhinney and Tomkin, 1971; Walker-Smith, 1971) and that tests for serum IgA
antibody are of no use in the detection of coeliac disease in these individuals. IgG
reticulin antibodies have been found in 94% of those with gluten sensitive enteropathy
and IgA deficiency (Collin et al, 1992b), whereas this class of reticulin antibody is
found in only 59% of non-lgA deficient patients (Maki et al, 1984b). IgG endomysium
antibody are present in only 15% of coeliacs with normal IgA levels (Beutner et al,
1989), but Beutner et al (1989) described an IgA deficient patient with coeliac disease
in whom IgG endomysium antibodies were present. I therefore modified the IgA EmA
test to develop a technique for detecting the IgG-class of antibody which I would then
have available if any patients of interest were IgA deficient.
This work was carried out by myself and Mr John Bode.
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Development of the IgA Endomysium Antibody Assay
We developed the technique of indirect immunofluorescence against human umbilical
cord based on that described by Ladinser et al (1994).
Fresh human umbilical cord was collected immediately after birth and cut transversely
into 5mm blocks, embedded in embedding compound (Cyro-M-Bed, Bright Instrument
Co Ltd, UK) and quick-frozen using Cryospray 22 (Bright Instrument Co Ltd, UK). The
blocks were stored at -70°C, and appear not to deteriorate over many months. 8(j.m
thick sections were cut using a cryostat at -15 to -20°C and placed on multispot slides
coated with 0.1% poly-L-lysine (Sigma Chemical Co Ltd, UK). The sections were
allowed to dry at room temperature for 30 minutes before wrapping the slides in
aluminium foil and storing at -20°C. In order to assess how stable the sections were at
this temperature, a batch of slides were kept for three months before being used with
serum which had already tested positive. They did not deteriorate over this period of
time.
After removing from the freezer the slides were allowed to reach room temperature
whilst still wrapped in foil. This avoided the formation of condensation on the sections.
Following a drying period at room temperature for 30 minutes the sections were fixed
in a jar of dried acetone at -20° for 10 minutes followed by chloroform at room
temperature for 30 minutes. The sections were then allowed to dry at room
temperature for 30 minutes, and at this point the serum identification number was
written on the top of the slide, and a circle was drawn around the section with a "PAP"
pen (Dako Ltd, UK). From this point onwards the sections were not allowed to dry out
again.
Initially we used phosphate buffered saline (PBS) with 0.05g bovine serum albumin
(BSA) for making up serum and conjugate dilutions. We later found that ELISA diluent
(0.09% saline, 0.05% Tween 20 and 1% adult bovine serum) had no adverse effects
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on the assay, and using this diluent enabled us to perform both antigliadin and
endomysium antibody assays on the same day, minimising the volume of serum
required and conserving time.
After fixing, non-specific staining was blocked by covering the sections with diluent for
10 minutes at room temperature. The excess was then removed and 50pl of the
serum was applied. Initially serum was applied without dilution, but this produced a
great deal of background staining which interfered with reading the sections. Several
dilutions were tried in order to find the optimum, and we finally agreed with Ladinser et
al and used a dilution of 1:5. The sections were incubated at room temperature for an
hour before rinsing with PBS and placing in a jar of PBS for 10 minutes on a rocking
table. After drying around the sections to reduce contamination of adjacent sections,
50pl of diluted conjugate was applied to the sections. We used FITC labelled rabbit
anti-human IgA (Scottish Antibody Production Unit, UK). Initially a dilution of 1:10 was
used, and again this produced a great deal of background staining. A dilution of 1:50
produced only faint fluorescence with positive sera, and so an optimum dilution of 1:20
was used in subsequent assays. The sections were incubated for one hour in a dark
staining box before placing in a jar of PBS and rinsed with running water for 10
minutes. The slides were again dried around the sections and mounted onto cover-
slip with warm glycerol gelatin.
The sections were read in the early stages using a Wild M50 fluorescence microscope
with a x10 objective. This microscope used a dark ground condenser on which a drop
of immersion oil was applied. The slide was then placed on the condenser and read
by two independent observers (myself and John Bode). The cord blood vessels were
located and fluorescence looked for within the smooth muscle of the vessel walls. If
fluorescence was found the sample was said to be positive for IgA endomysium
antibody, and was negative in the absence of the fluorescence. The result was
accepted as true if both observers agreed.
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In May 1996 the laboratory purchased a new fluorescence microscopy (Hund H500,
Hund, Germany) which does not use a dark ground condenser. The light intensity
therefore does not decrease with a higher objective, enabling a greater appreciation of
the pattern of fluorescent staining within the smooth muscle at x25 magnification
(picture 4.1). Initially sections were read using both microscopes and no discrepancies
in results were found between the two.
Validation of the IgA Endomysium Antibody Assay
The assay was performed on 97 serum samples to establish whether it could be
added to the laboratory's NHS analytical service. Over several years serum has been
stored on all patients undergoing jejunal biopsy and 51 of these historical samples
were tested. In addition, 46 samples from patients undergoing investigation for
possible coeliac disease were tested prospectively. All of these patients were taking a
normal gluten containing diet and pathology reports of small bowel biopsy taken on the
same day as the blood sample were available on all of them.
55 patients were confirmed to have coeliac disease. We found that of these, 48 were
positive for IgA endomysium antibody, three were negative and four had equivocal
results. Of the three with negative assays, two patients had selective IgA deficiency
and one had dermatitis herpetiformis with subtotal villous atrophy on small bowel
biopsy.
40 patients had entirely normal biopsies and 37 of these were negative for the
antibody.
The two remaining patients were found to be positive for IgA endomysium antibody
and their small bowel biopsies were reported as normal by the Pathologist. My
predecessor, Dr Eduardo Arranz had performed formal IEL counts on these biopsies
and had found them to be raised.
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Picture 4.1: Typical fluorescence produced by endomysium antibody within the
smooth muscle of the umbilical cord vessels
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In order to calculate the sensitivity and specificity of the assay we excluded patients
with equivocal assay results, IgA deficiency and those with isolated high IEL counts.
The results are shown in table 4.1. The sensitivity was calculated to be 98% and the
specificity 92.5%.
Not Coeliac Coeiiac
Negative EmA 37 1
Positive EmA 3 48
Total 40 49
Table 4.1: Figures used to calculate sensitivity and specificity of the IgA endomysium
assay in patients who had small bowel biopsy to establish the presence or absence of
coeliac disease
Monitoring the Routine Use of the Assay
The IgA endomysium antibody assay was added to the laboratory's routine service on
1 January 1995. All samples submitted for antigliadin antibody measurement were
also tested for endomysium antibody. After the first year of the service the results
were reviewed.
In the twelve month period, 838 samples were analysed. 62 were positive for IgA
endomysium antibody and the clinicians responsible for these patients were contacted
to see if the patients had undergone small bowel biopsy. The ensuing feedback is
demonstrated in table 4.2. 44 patients with negative antibodies also underwent biopsy
and their results are shown in table 4.3. The formal IEL counts were performed by
myself on these biopsies.
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Biopsy Findings Number of Patients
Normal 2
Increased IEL only 6
Partial villous atrophy 5
Sub-total villous atrophy 19
Total villous atrophy 3
Previously proven coeliac 16
Empirical GFD with clinical response,
no small bowel biopsy performed
4
No biopsy performed 2
No reply from clinician 5
Table 4.2: Biopsy findings in 62 patients positive for IgA endomysium antibody
Biopsy Findings Number of Patients
Normal 34
Increased IEL only 7
PVA (no improvement with GFD) 1
STVA and IgA deficiency 2
Table 4.3: Biopsy findings in 44 patients negative for IgA endomysium antibody
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The patient negative for the antibody and with partial villous atrophy on biopsy was a
man with Crohn's colitis and primary sclerosing cholangitis who was treated with
azathioprine. His small bowel biopsy was not felt to be classical for coeliac disease
but he underwent a trial of gluten free diet. He failed to respond to the withdrawal of
gluten and was therefore classified as a non-coeliac individual.
In order to calculate the sensitivity and specificity of the assay over the first year of its
use we excluded patients with isolated high IEL counts, those with IgA deficiency and
those in whom biopsy had not been performed. The figures used for calculation are
shown in table 4.4. The sensitivity was calculated at 100% and specificity at 94.6%.
Not coeliac Coeliac
Negative EmA 35 0
Positive EmA 2 43
Total 37 43
Table 4.4: Figures used to calculate specificity and sensitivity of the IgA endomysium
antibody assay for patients who had serum sent for antibody testing over the first year
of its routine use.
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IgA Endomysium Antibody and Raised IEL Counts
In Chapter 3 I described 23 patients not known to have coeliac disease who had a
raised IEL count as the only abnormality in their small bowel biopsy. Eight of these
patients saw an improvement in symptoms on a gluten free diet, and three of this
group had repeat duodenal biopsies in which the IEL count had returned to normal. In
order to see if IgA endomysium antibody could predict individuals who would respond
to this treatment I tested archived serum for the antibody. I tested serum from 20
patients, seven with self-limiting symptoms, eight in whom symptoms improved with a
gluten-free diet, three who refused GFD, one who did not respond to the diet and one
from a patient who responded to treatment for bile salt malabsorption. The results are
shown in table 4.5.
Nearly 40% of the patients who responded to the diet but none of the those with self-
limiting symptoms had IgA endomysium antibody. The individual who did not respond
to the diet was negative for the antibody. This suggests that the presence of IgA
endomysium antibody in such a patient will predict a response to GFD, but its absence
does not predict a lack of response.
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Patient Outcome IgA EmA
VC Diarrhoea resolved and IEL count
returned to normal on GFD
Positive
LM Anaemia resolved and IEL count
returned to normal on GFD
Positive
MB Anaemia resolved on GFD Positive
RM Diarrhoea resolved and IEL count
returned to normal on GFD
Negative
KM Diarrhoea resolved and IEL count
returned to normal on GFD
Negative
GF Diarrhoea resolved on GFD Negative
KT Diarrhoea resolved on GFD Negative
FA Diarrhoea resolved on GFD Negative
CR No clinical improvement with GFD Negative
MB Refused GFD Negative
JT Refused GFD Negative
AJ Refused GFD - Anaemia treated with
iron
Negative
CP Self-limiting symptoms Negative
JB Self-limiting symptoms Negative
DM Self-limiting symptoms Negative
FM Self-limiting symptoms Negative
PT Self-limiting symptoms Negative
EM Self-limiting symptoms Negative
NR Self-limiting symptoms Negative
MG Diarrhoea resolved with cholestyramine Negative
Table 4.5: IgA endomysium antibody in 20 individuals with raised IEL counts but
normal small bowel mucosal architecture
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IgA Endomysium Antibody in Whole Gut Lavage Fluid
Antigliadin and reticulin antibodies have been detected in intestinal secretions(Volta et
al, 1988; O'Mahony et al, 1991; Mawhinney and Love, 1975) in coeliac disease and
endomysium antibody has been found in organ culture medium after stimulation of
small intestinal biopsy culture with gliadin. I therefore went on to examine whole gut
lavage fluid for IgA EmA.
Samples
Whole gut lavage fluid (WGLF) had previously been collected and processed
according to the standard methods described in Chapter 2 from nine patients known to
have coeliac disease and one patient in whom IgA EmA was found whilst screening
serum from a group of patients from the Gastrointestinal Unit. In addition, stored
WGLF was tested from three patients who were non coeliacs. Serum had been
collected at the same time as the lavage fluid and stored at -20°C.
Our standard technique was used for the measurement of IgA EmA in serum, and the
only alteration made for WGLF was in the sample dilution. As WGLF is relatively
dilute at the time of collection this was added to the umbilical cord sections without
further dilution. The conjugate was added at 1:20 dilution as before and the sections
read by two independent observers.
Results
IgA endomysium antibody was found in the serum of two patients, both on normal
diets, and was also present in the lavage of both these individuals. A third patient,
who was taking a gluten free diet, was negative for IgA EmA in serum, but was
positive in lavage. The details are shown in table 4.6. The remainder of the patients
were negative for the antibody in both serum and lavage.
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Conclusion
In a recent paper McCord and Hall (1994) found IgA endomysium antibody in lavage in
patients with dermatitis herpetiformis, but only in those individuals with the antibody
present in serum. The finding of IgA EmA in lavage but not in serum in one of our
patients on a gluten free diet further supports the view of mucosal production of this
antibody. The titre may not be high enough to produce "spill over" into the peripheral
blood, whereas this may well be the case in the two patients on normal diet with
positive antibodies in both samples.
Patient Diet Serum IgA EmA WGLF IgA EmA
PR Normal +++ +++++
IR Normal +++ +++++
MW GFD - ++++
AJ GFD - -
EB GFD - -
EK GFD - -
JP GFD - -
JD GFD - -
MF GFD - -
PB GFD - -
JM Non coeliac - -
EF Non coeliac - -
Non coeliac - -
Table 4.6: Serum and WGLF IgA endomysium antibody in nine coeliac, three non-
coeliac patients and one patient found positive for IgA EmA on screening.
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Development of the Method for Measuring IgG Endomysium Antibody
As I have mentioned, selective IgA deficiency is associated with coeliac disease, and
those individuals with IgA deficiency have a tenfold risk of developing coeliac disease
(Collin et al, 1992b). In view of this, we have adapted the method used for detecting
IgA EmA for detecting the IgG-class of the antibody.
The frozen sections of human umbilical cord were fixed and blocked in the same way
as with the IgA assay and diluted serum applied. Various dilutions of serum were
tried, but a 1:10 dilution was found to be the most effective, reducing non-specific
binding without the loss of accuracy. Following incubation at room temperature in a
moist staining box for one hour the sections were rinsed with PBS and placed in a
PBS bath for 10 minutes on a rocking table. FITC labelled rabbit anti-human IgG
conjugate was then applied. A dilution of 1:20 increased the amount of background
colouring, interfering with interpretation of the slides, and so a dilution of 1:40 was
used. This improved the assay, but still produced prominent background staining. A
conjugate dilution of 1:100 was found to be the most effective. After one hour's
incubation at room temperature in a moist, dark staining box the sections were again
washed and mounted onto coverslips with warm glycerol gelatin. The sections were
read using a microscope fitted with UV light source, and were said to be positive if
honeycomb fluorescence was seen within the smooth muscle of the cord vessel walls,
and negative if this fluorescence was absent.
Results of the IgG Endomysium Antibody Assay
We initially used this assay to test the serum of a 44 year old woman with coeliac
disease and abnormal serum immunoglobulins. She had intractable diarrhoea dating
back to 1979, severe enough to cause the breakdown of her marriage. She
underwent investigation at her local hospital and was found to have sub-total villous
atrophy of the jejunal mucosa in the absence of antigliadin antibodies. There was a
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reduction of total immunoglobulins of IgA-, IgG- and IgM-classes, but predominantly of
the IgA-isotype.
She was referred to our hospital for further investigation as she failed to improve
despite a strict gluten free diet and oral prednisolone. We measured her IgG-class
coeliac related antibodies and found positive IgG endomysium antibody and a
moderate titre of IgG antigliadin antibody (46U with the normal range of up to 45U). A
repeat small bowel biopsy confirmed sub-total villous atrophy and intestinal
permeability was raised when tested using a lactulose/rhamnose sugar permeability
test. The remainder of her investigations, including whole gut lavage, stool culture and
pancreatic function tests, were all normal.
She was treated initially with elemental diet with an improvement in her symptoms and
the loss of serum IgG endomysium antibody. On withdrawal of the elemental diet her
diarrhoea returned and so treatment with cyclosporin was commenced. This has
produced good clinical and histological responses and her IgG endomysium antibody
remains negative.
In this patient the presence of IgG endomysium antibody helped confirm the diagnosis
of refractory coeliac disease and its subsequent disappearance on response to
cyclosporin treatment has been used to monitor her clinical progress.
I tested 38 serum samples positive for IgA endomysium antibody for IgG EmA to
assess how frequently both classes of the antibody occurred. Seven (18%) were
positive for both classes of the antibody, but the remainder were negative for the IgG-
class. Despite the small number of samples, this figure is in keeping with the findings
of Beutner et al (1989).
49 samples negative for IgA EmA were also tested for the IgG-class antibody. Seven
samples were positive for IgG EmA, all from individuals with IgA deficiency. Four were
known to have coeliac disease, and the other three went on to have jejunal biopsies
which revealed sub-total villous atrophy in each case.
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It would appear, therefore, that the adaptation of the IgA endomysium antibody assay
to detect the IgG-class of antibody provides a useful tool for the detection of coeliac
disease in those individuals with IgA deficiency. IgG EmA occurs infrequently in non-
IgA deficient individuals with coeliac disease making the test of little diagnostic use in
these individuals. This lack of the IgG-class in those with normal IgA levels suggests
recruitment of IgG plasma cells in the absence of IgA cells.
The Use of Dried Blood Spots in the Detection of Coeliac Disease
The use of serum or plasma for detecting coeliac related antibodies in large
populations presents several different problems. The patient needs to have a formal
venepuncture performed in order to obtain the blood, and not only is this a painful
procedure for the individual, but also requires training of the member of staff
performing the procedure. The blood needs to be collected into a suitable blood tube,
sealed in a polythene bag, and then sent to the laboratory performing the assay. The
sample must arrive in the laboratory within a few days to ensure that it has not
deteriorated, and must then be centrifuged and the serum or plasma separated into a
second sample tube which then requires freezing. The equipment required for the
whole procedure and the delivery of the sample to the laboratory obviously have cost
and manpower implications. The storage of large numbers of sera or plasma also
presents problems providing suitable sub-zero storage space.
In view of these problems, we have looked at the possibility of using dried blood spots,
obtained from a fingerprick, in the antigliadin and antiendomysium antibody assays.
Dried blood spots are used extensively in newborn children for detecting inborn errors
of metabolism, such as phenylketonuria and hypothyroidism. The advantages they
offer over venepuncture samples for screening large populations are the relative
inexpense of the equipment (a lancet for performing the finger or heel prick, and a
compressed filter paper card), the less invasive method of obtaining the blood sample,
the ease of sending multiple samples through the ordinary post if the distance from the
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laboratory is great, the increased stability of the sample, the reduced storage space
required and the lesser demands on manpower.
Previous work by Mrs Louise Handy, Mr Norman Anderson and Dr Nick Croft has
looked at the possibility of measuring IgA and IgG antigliadin antibodies from dried
blood spots using standard compressed filter paper cards. They have looked at the
development of a technique for eluting serum from the spots and using the eluate in
the antigliadin ELISA. This initial work looks very promising, with little variability
between different spots taken from the same serum sample and excellent stability of
the samples stored at room temperature and 4°C over many months. Mrs Handy
went on to examine spots made from 40 whole blood samples and compared the
antigliadin titres in the eluates to those in plasma from the same sample. The samples
were eluted by a method based on that of Tappin et al (1991). A 5mm disc was
punched from the centre of the spot and placed into a microtitre well containing 200|als
of elution buffer (PBS, 0.05% Tween 20 and 0.05% sodium azide). The plate was
shaken on an ELISA mixer for 30 minutes before and after an overnight incubation at
4°C. The eluate was then taken from the well and used in the antigliadin antibody
ELISA assays at a dilution of 1:5. The titres were then compared to those in plasma
by linear regression and correlation coefficients of r2=0.576 and ^=0.787 were
calculated for the IgA and IgG assays respectively. These positive results led on to my
development of a technique for measuring IgA endomysium antibody on similar
material.
Development of the Method for Measuring IgA Endomysium Antibodies in Dried
Blood Spots.
Paired whole blood and serum samples were collected from 12 patients attending the
Gastrointestinal Unit for investigation; four with proven coeliac disease and eight non-
coeliacs. Serum antiendomysium antibodies were measured by indirect
immunofluorescence against human umbilical cord using the method described earlier.
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In order to measure antiendomysium antibodies from dried blood spots the sections of
cord were fixed and blocked in the same way. Initially the dried blood spots were
eluted as described above and the eluate applied to the section of umbilical cord
without dilution. The sections were incubated at room temperature for one hour prior
to washing and application of the conjugate. This method did not produce positive
results and I felt this was due to a combination of failing to elute all of the antibody
from the spot and over-dilution of the material by using a volume of 200pls for elution.
I therefore attempted to elute the spot directly onto the sample. After fixing and
blocking, 75pl of a solution was applied to each section. A 5mm disc was punched out
of the centre of the filter paper circle and "floated" on the liquid. The sections were
then incubated overnight at 4°C. Initially I used the original endomysium assay diluent,
namely PBS with bovine serum albumin, but found that the sections were either
negative or equivocal but never positive. This was not improved by using ELISA
diluent, but the use of elution buffer did improve the quality of the results. I found that
better elution was achieved after shaking the slides on an ELISA mixer for 30 minutes
prior to the overnight incubation. Before washing the next day the slides were again
shaken for 30 minutes. The conjugate and coverslips were applied as before.
The sections were read blindly by two independent observers, looking for honeycomb
fluorescence within the cord vessel smooth muscle. Results were accepted if both
observers agreed.
The results of the twelve paired samples are shown in table 4.7. In all cases the results
of the serum sample and the dried blood spot agreed. The eight non-coeliac patients
were all negative for IgA endomysium antibody, and the four with coeliac disease were
all positive for the antibody. The degree of positivity varied between serum and dried
blood spot, but this is a very subjective measurement and is likely to be very
inaccurate. In all cases, however, the antibody could be described as "strongly
positive".
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I found that positive staining within the vessel smooth muscle occurred in the same
pattern as seen with serum, but strong fluorescence also occurred within the
connective tissue around the vessels. It would appear that this connective tissue
deteriorates overnight and holes develop within the tissue. Fluorescent staining then
occurs at the edges of these holes, as if endomysium is exposed during this
degenerative process.
IgA antiendomysium antibody















Table 4.7: Comparison of IgA endomysium antibody assay results in serum and dried
blood spot samples from 12 patients
Summary
In summary, therefore, we have shown that it is possible to detect coeliac related
antibodies in material eluted from dried blood spots. Initial studies revealed good
correlation between the titres of antigliadin antibodies from the blood spots compared
with plasma. Excellent correlation was also found between blood spot and serum
results in the IgA endomysium antibody assay.
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Obviously, these experiments were carried out on small numbers of samples, but the
positive results are encouraging and work on these assays is continuing. The blood
spots were also produced in ideal conditions, exactly 50pls of blood was pipetted onto
each spot. This will not be the case in clinical practice and so future experiments
should include material obtained by the patient him/herself to see if under-filled spots
will affect the results of the assay. We also need to look at the amount of material
eluted from the blood spots to see if this varies with different conditions.
I think these techniques show a great deal of promise for use as screening tools in the
future. In newborns dried blood spots are used as an initial test for inborn errors of
metabolism and positive or equivocal results are followed up by repeating the tests on
venepuncture samples. I am sure this practice should also be followed in the case of
coeliac disease screening by this method.
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CHAPTER 5: THE USE OF ANTIGLIADIN AND ENDOMYSIUM ANTIBODIES IN
SCREENING FOR COELIAC DISEASE
Introduction
As I have already mentioned, both antigliadin and tissue antibodies have been used to
screen for coeliac disease in both normal and "at risk" populations (Friis and
Gudmand-Hoyer, 1986; Uibo et al, 1993; Vazquez et al, 1996; Deseta et al, 1995;
Ribes et al, 1991; Vitoria et al, 1994; Calero et al, 1996; Maki et al, 1984a; Page et al,
1994; Sategna-Guidetti et al, 1994; Nosari et al, 1996). Very few studies however,
have looked at hospital populations and so, once our endomysium antibody assay had
been established, we screened a population of hospital patients for coeliac disease.
Following on from this we went on to screen two insulin-dependent diabetic
populations and a group of individuals with Down's syndrome.
HOSPITAL POPULATION
Materials and Methods
300 whole blood samples were obtained from the hospital Haematology laboratory.
These samples had all been sent to the laboratory for full blood count estimation and
the residual sample was used for coeliac disease screening. The whole blood was
centrifuged at 2500 rpm for 10 minutes before separating the plasma, which was then
stored at -20°C. In addition, 600 stored serum samples were also used. These had
been collected from patients attending the Gastrointestinal Unit for investigation over
the previous three years and had been stored at -20°C.
The samples were initially tested for antigliadin antibodies, plasma by Brian Walker
and Louise Handy as part of a special study module and serum by Norman Anderson.
Any samples with high IgA antigliadin antibody titres were also tested for IgA
endomysium antibodies.
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The physician responsible for sending any positive sample was contacted for patient
details and further investigation for the patient offered.
Results
Haematology Samples
41 samples were found to have IgA antigliadin antibody titres over 30U and all were
tested for IgA endomysium antibody. These results along with the clinical details given
to the Haematology laboratory are shown in tables 5.1 and 5.2.
Eleven patients tested positive for IgA endomysium antibody, one of whom was
already known to have coeliac disease. The remaining 27 samples were negative.
There was no significant difference between the IgA antigliadin antibody titres in the
two groups using the Mann-Whitney test.
Patient Age Clinical Details AGA (U) AEA
1 47 Alcoholic liver disease 47 Positive
2 84 Alcoholic liver disease 73 Positive
3 67 Alcoholic liver disease 87 Positive
4 51 Alcoholic liver disease 42 Positive
5 69 Neuropathy, alcoholic liver disease 106 Positive
6 55 Coeliac 31 Positive
7 80 "On warfarin" 54 Positive
8 95 Weight loss, diarrhoea 60 Positive
9 80 Pneumonia 97 Positive
10 77 Gastric carcinoma, pernicious anaemia 193 Positive
11 89 Anaemia 36 Positive
Table 5.1: Results and clinical details of patients in the haematology group with IgA
antigliadin antibody titres of >30U and positive IgA endomysium antibody
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Patient Age Clinical Details AGA (U) AEA
1 29 Crohn's disease 66 Negat ve
2 77 Cardiac Failure 40 Negat ve
3 64 Idiopathic thrombocytopenia 31 Negat ve
4 Post natal 40 Negat ve
5 75 Polymyalgia Rheumatica 35 Negat ve
6 76 "On iron" 35 Negat ve
7 67 Gout 46 Negat ve
8 65 Pre-operative 32 Negat ve
9 73 Sub-dural haematoma 98 Negat ve
10 68 Rheumatoid arthritis 33 Negat ve
11 62 Inflammatory bowel disease, arthritis 118 Negat ve
12 30 Pregnant 45 Negat ve
13 75 Diverticulitis 53 Negat ve
14 63 Diverticulitis, Ischaemic heart disease 53 Negat ve
15 71 Abdominal pain 54 Negat ve
16 63 Pre-operative 44 Negat ve
17 33 Cystic fibrosis, heart and lung
transplant
58 Negat ve
18 49 Rheumatoid arthritis 41 Negative
19 58 Stroke, on warfarin 42 Negative
20 81 Type I diabetes, ?pulmonary embolism 37 Negative
21 65 Breathlessness 91 Negative
22 68 Rheumatoid arthritis 32 Negative
23 30 Rectal bleeding 88 Negative
24 83 Renal failure and oedema 42 Negative
25 81 Altered bowel habit 57 Negative
26 65 Myeloma 45 Negative
27 26 Chronic myeloid leukaemia 40 Negative
Table 5.2: Results and clinical details of patients in the haematology group with IgA
antigliadin antibody titres of >30U and negative IgA endomysium antibody
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Gastrointestinal Unit Samples
Of the 600 samples tested, 93 had high IgA antigliadin antibody titres and were tested
for IgA endomysium antibody. 16 were positive for IgA EmA and their details are
shown in table 5.3. Seven of these patients were already known to be coeliac, and
one patient had dermatitis herpetiformis.
Patient Diagnosis made in Gl Clinic AGA (U)
1 Bronchial carcinoma, diarrhoea 63
2 Bacterial colonisation 371
3 Depression, Irritable bowel syndrome 64
4 Alcoholic liver disease, angiodysplasia 68
5 Colonic carcinoma 30
6 Ulcerative colitis, Ischaemic heart disease 41
7 Bile salt malabsorption, Type II diabetes 33
8 Angiodysplasia, Iron deficiency anaemia 30
9 Dermatitis herpetiformis 31
10 Coeliac Disease >400
11 Coeliac Disease >400
12 Coeliac Disease 109
13 Coeliac Disease >400
14 Coeliac Disease 41
15 Coeliac Disease 142
16 Coeliac Disease >400
Table 5.3: Clinical details and IgA antigliadin antibody titres of Gl patients found
positive for IgA endomysium antibody
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Follow up of Patients with Positive Results
In total there were 18 patients positive for both antibodies from the two groups who
were not known to have coeliac disease or DH. Five of the patients from the
Haematology group and one from the Gl group had alcoholic liver disease. Of these
two had died soon after the sample had been collected and one was too unwell to
have further investigations. The remaining three patients all underwent endoscopic
duodenal biopsy and in each case the mucosa was normal.
The follow up of the remaining 12 patients is shown in table 5.4:
Clinical Details No of Patients Outcome
Diarrhoea, thryroid disease 1 Small bowel biopsy confirmed
coeliac disease
Ulcerative colitis 1 No biopsy taken
Diarrhoea 2 Resolved with drug therapy
Iron deficiency anaemia 1 Refused investigation
Angiodysplasia, on warfarin 1 Not biopsied in view of
anticoagulation
Malignancy 3 Died
No reply from Physician 3
Table 5.4: Outcome of follow up of 12 patients from the two groups with positive IgA
EmA and raised IgA antigliadin antibody
Summary
From our original pool of over 900 samples we found one new case of coeliac disease.
The data illustrate the difficulties encountered in screening a population for coeliac
disease. Many of the patients were elderly and often had several co-existing illnesses
making further investigation difficult. As many of the samples were several months or
even years old by the time they were tested patients had been lost to follow up or had
died.
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I was surprised by the high number of patients with alcoholic liver disease who were
positive for IgA EmA, especially as the three who were biopsied had normal small
bowel morphology and IEL counts. I therefore went on to investigate the possibility of
alcoholic liver disease producing a false positive endomysium assay, and this work is
presented in Chapter 6.
INSULIN-DEPENDENT DIABETIC POPULATION
Increasingly it is recognised that insulin-dependent diabetes mellitus (IDDM) and
coeliac disease are associated. Several studies have screened insulin-dependent
diabetics using antigliadin antibodies and have found the prevalence of coeliac
disease to be between 1.7 and 16% (De Vitis et al, 1996; Boudraa et al, 1996; Collin
et al, 1989; Barera et al, 1991; Page et al, 1994) and using reticulin antibodies puts
the prevalence at 1.4-3.8% (Maki et al, 1995; Saukkonen et al, 1996; Savilahti et al,
1986; Maki et al, 1984a). More recently IgA endomysium antibody has been used for
screening and has found coeliac disease in 3.13-6.4% of type I diabetics (Rensch et
al, 1996; Sategna-Guidetti etal, 1994; Nosari et al, 1996).
We have looked at two groups of patients with insulin-dependent diabetes, adults
attending the Edinburgh Royal Infirmary and children attending the Royal Hospital for
Sick Children, using a combination of IgA antigliadin and endomysium antibodies.
Sample Collection
Adults
Blood was taken from all patients with type I diabetes attending the diabetic clinic
between March 1996 and January 1997 by the clinic nursing staff. In total 607
samples were received, and all were centrifuged and serum separated before storing
at -20°C prior to analysing.
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Children
All the children and their parents attending the paediatric diabetic clinic were
approached between August 1996 and January 1997. They were given written and
verbal information regarding the association between IDDM and coeliac disease.
In Edinburgh the monitoring of children with diabetes is primarily using capillary blood
obtained by fingerprick to measure glycosylated haemoglobin (HbAiC) and annual
thyroid function tests. In view of this I decided to use capillary plasma to measure
coeliac antibodies in order to avoid venepuncture.
Children having blood taken in the clinic were asked if I could collect an additional
sample at the same time, and those not having blood were asked to send in a sample
collected at home. For the home collection kit I included a filter paper card in addition
to the capillary tube and asked that both be used in order to ensure a sufficient
quantity of blood was received.
Capillary blood was collected into a Microvette CB300 lithium heparin tube (Sarstedt,
Germany). Once received in the laboratory the samples were centrifuged at 2500 rpm
for five minutes and the plasma separated and stored at -20°C prior to testing. Dried
blood spot samples were stored in a polythene bag at 4°C. In total 130 samples were
received from the 161 children approached (80.1%).
Methods
All samples were tested for IgA antigliadin and endomysium antibodies using the
techniques previously described. Serum was tested at 1:5 dilution and plasma at 1:10
dilution for the endomysium assay, but all were tested at 1:100 dilution for the
antigliadin assay.
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Any patients with positive endomysium antibodies were contacted and offered an
outpatient appointment to discuss the implications of the positive results before further
investigations were arranged.
Results
IgA endomysium was found in 17 adult samples and one paediatric sample. All the
patients and their general practitioners were contacted and offered further
investigation. One patient did not attend her clinic appointment. The clinical details of
the remaining 17 patients are shown in table 5.5. Five patients were completely
asymptomatic but of these, only one had completely normal haematological and
biochemical parameters. Twelve patients did have symptoms, ranging from mild
abdominal bloating to severe diarrhoea and vomiting. One man, aged 77, had iron
deficiency anaemia and coexisting pernicious anaemia, but also suffers from
haemophilia A and so was not offered biopsy. He was advised to reduce his gluten
intake as much as possible in addition to his iron supplementation. The patient found
from the paediatric clinic also had severe symptoms of diarrhoea, vomiting and
abdominal pain leading to many lost school days. She was failing to gain weight and
her diabetic control has been very poor over the last two years. Her symptoms have
improved on a gluten free diet and she is now gaining weight.
the commonest biochemical abnormality was hypomagnesaemia, found in ten of our
17 patients. I was surprised by this finding, as hypomagnesaemia is relatively
uncommon in our clinical experience of coeliac disease. I wonder if this is due to
increased renal losses of magnesium occurring in diabetes and the inability of the
bowel to compensate for this by increasing absorption. I have not looked for a
correlation between these results and the finding of microalbuminuria, but this would
be worthwhile. Hypocalcaemia was not seen in any of our patients. Thyroid
antibodies were found at an equivocal titre in three asymptomatic female patients, but
no other organ specific autoantibodies were found.
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At the time of submission of this thesis, biopsy findings are outstanding in most of the
patients, but are available in four. Only one patient had findings of classical coeliac
disease with villous atrophy, crypt hyperplasia and increased IEL. One patient was
reported to have an entirely normal biopsy, and an IEL count was performed which
was normal. A second biopsy was taken for crypt microdissection by Dr Quaioling
Liang and this showed shortening of the villi, lengthening of the crypts and an
increased in the number of mitotic figures within the crypts. Two patients were
reported to have increased numbers of IEL and formal counts of these biopsies are
outstanding. These biopsies also showed patchy crypt lengthening on micro¬
dissection. Counts of CD3+ and yS+ IEL are still awaited on all these biopsies.
Summary
Testing a general hospital population failed to find any new cases of coeliac disease,
but did lead to the finding of high IgA antigliadin titres and positive IgA endomysium
antibodies in a number of patients with chronic liver disease. One patient who had
attended the gastrointestinal clinic several years ago was confirmed to have coeliac
disease and a second patient with inflammatory bowel disease is awaiting endoscopic
biopsy to confirm the diagnosis as a result of this testing.
In the insulin-dependent diabetic population, 17 adults and one child were found to
have endomysium antibody and an unexpectedly high number were found to have
gastrointestinal symptoms. One patient has typical histological features of coeliac
disease and three have findings suggestive of gluten sensitivity. All these patients
have received dietetic advice regarding a gluten free diabetic diet and their progress
will be reviewed in the clinic.
Our findings support the view that antigliadin and endomysium antibodies should be
tested routinely in diabetic clinics to identify coexisting coeliac disease which may
result in significant morbidity in these patients.
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Patient Age Symptoms Haematology/Biochemistry Biopsy Findings
WA 77 Tiredness Iron deficiency anaemia,
hypomagnesaemia
Not done







AC 18 None Hypomagnesaemia Awaited
MD 41 Diarrhoea Iron deficiency, hypo¬
magnesaemia
Severe PVA




HH 39 Vomiting Hypomagnesaemia Awaited
AJ 66 None Iron deficiency, hypo¬
magnesaemia
Declined
BM 34 None Hypomagnesaemia Declined
KM 21 None Hypomagnesaemia Awaited
RM 35 Diarrhoea None Crypt lengthening,
IEL count 35/mm
EM 66 None Normal Declined
NS 23 Diarrhoea Hypomagnesaemia Declined






Iron deficiency anaemia Awaited
Table 5.5: Clinical details of 18 type I diabetics with positive IgA endomysium antibody
on screening.
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CHAPTER 6: ANTIGLIADIN AND ENDOMYSIUM ANTIBODIES IN CHRONIC LIVER
DISEASE
Introduction
Coeliac disease and primary biliary cirrhosis are known to be associated (Logan et al,
1978; Olsson et al, 1982). Lindgren et al (1994) have reported a higher incidence of
coeliac disease in a group of patients with cryptogenic cirrhosis but no other discrete
liver disease has been found in association with gluten sensitivity. I was therefore
surprised by the finding of positive IgA endomysium antibody in serum and plasma
from patients with alcoholic liver disease. Three of our six positive patients underwent
small intestinal biopsy which was normal in each case. This raised the possibility of
chronic liver disease producing a false positive result in our IgA EmA assay. I went on
to test 25 serum samples for this antibody from patients with chronic liver disease.
Materials and Methods
25 serum samples were obtained from individuals with chronic liver disease, both from
our own Unit and also from Dr Ruth Gillespie at the Royal Infirmary's Gastrointestinal
Unit. The diagnoses of these patients are listed in table 6.1. These samples were
tested for IgA antigliadin and endomysium antibodies.
Samples found to be positive for IgA EmA were assessed further by repeating the
endomysium assay at increasing dilutions to measure titres of the antibody. In
addition, total IgA levels were also measured by the hospital Biochemistry laboratory.
Results
Eight samples had raised IgA AGA titres and ten were positive for IgA EmA (table 6.1).
Four individuals agreed to undergo small intestinal biopsies, and all were entirely
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normal. Nine out of ten with positive IgA endomysium antibodies had raised total IgA
levels.
Diagnosis No. of No. with raised No. with positive
Patients AGA EmA
Alcoholic liver disease 10 6 7
Cryptogenic cirrhosis 8 2 2
Primary biliary cirrhosis 4 0 0
Chronic active hepatitis 2 0 1
Haemochromatosis 1 0 0
Table 6.1: Diagnoses of 25 patients with chronic liver disease tested for IgA EmA
When titres of IgA endomysium antibody were measured, all of the positive samples
had strong fluorescence present at 1:10 dilution, and one sample was still positive at
1:20. Five further samples exhibited fluorescence at 1:20, but these were felt to be
equivocal results. The remainder were clearly negative at this dilution.
Shortly after these experiments were carried out, the laboratory bought a new
fluorescent microscope (Hund H500) to replace our existing Wild M20 microscope.
This microscope does not use a dark ground condenser and enables a higher power
objective to be used without a reduction in light intensity. This enabled the sections to
be examined at higher power and led to the discovery of a different pattern of staining
within the cord vessels. The antibodies present in chronic liver disease appear to be
directed against nuclear fragments of the smooth muscle cells (picture 6.1) and are
therefore not endomysium antibodies.
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From this group of patients it is evident that individuals with chronic liver disease have
a higher prevalence of IgA antigliadin antibodies than the normal population. It would
appear that chronic liver disease is not associated with false positive IgA endomysium
antibodies, and that the earlier findings during the screening of hospital samples were
due to the examination of the umbilical cord under low power magnification and our
failure to appreciate the difference in patterns of fluorescence. This fluorescence may,
however interfere with the interpretation of the microscopy of the section and
increasing the dilution of the serum will not necessarily eliminate the fluorescence. It
may, in fact, increase the number of false negatives seen in those with coeliac
disease. The high total IgA levels would suggest that the high titres of antigliadin
antibodies are due to polyclonal expansion of IgA rather than a specific response to
gliadin.
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CHAPTER 7: RECTAL GLUTEN CHALLENGING USING A RECTAL WASH
TECHNIQUE
Introduction
The original ESPGAN criteria for the diagnosis of coeliac disease included the
reappearance of pathological changes in the small bowel mucosa in response to
reintroduction of gluten in the diet (Meuwisse, 1970). In 1979 these criteria were
reviewed, and it was found that gluten challenge was routinely performed by only two
thirds of the members of ESPGAN (McNeish et al, 1979). It was also suggested that
gluten challenge was not required in all cases as it confirmed the original diagnosis
made by the first biopsy in 95% of cases.
Gluten challenging traditionally involves either the addition of 10-15g of gluten powder
per day to the food, or allowing the patient to eat 3-4 slices of normal bread per day. A
minority of patients develop severe symptoms, but most remain asymptomatic for
several weeks or months (McNicholl et al, 1979). A small bowel biopsy is taken when
the patient becomes symptomatic, or at three to six months, but even at this point the
mucosa may remain normal and there have been reports of the mucosa relapsing only
after several years of gluten containing diet (McNicholl et al, 1979; Shmerling and
Francx, 1986; Polanco and Larrauri, 1990). Measurements of antigliadin or tissue
antibodies have been used to predict mucosal relapse and to time small bowel biopsy
(Maki et al, 1989).
Abnormalities can be found in the rectal mucosa in 5% of patients with coeliac disease
(Rubin et al, 1962), and these are thought to be a cell mediated response to gluten
antigens present in the faecal stream. Inducing histological changes by exposing the
rectal mucosa to gluten has been examined by several groups in the hope that this will
provide an alternative to oral gluten challenging in individuals where the diagnosis of
coeliac disease is uncertain. These studies have shown rapid histological changes
occurring in the rectal mucosa in response to gluten, but these changes are often
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subtle, requiring computerised image analysis to detect them. In order for rectal gluten
challenging to be used as a routine diagnostic tool in the diagnosis of coeliac disease
it should use a readily available, minimally invasive technique. I devised a method of
retrieving rectal mucosal secretions using polyethylene glycol and examined whether
changes in protein and immunoglobulin secretion could be detected in response to
exposure of the mucosa to gluten.
Development of the Technique for Retrieving Rectal Mucosal Secretions
In our laboratory whole gut lavage is a standard technique used for the investigation of
blood loss and gut inflammation. This technique is described in detail in Chapter 2,
but in brief the patient drinks a large volume of polyethylene glycol plus electrolyte
solution (PEG+E) at a steady rate of one litre per hour. Clear fluid passed per rectum
is collected and analysed for haemoglobin, albumin, a-1-antitrypsin and total IgG. I felt
that if PEG+E could be instilled into the rectum and retrieved after a few minutes, it
would collect secretions produced by the rectal mucosa which could then be analysed
by our standard laboratory methods.
Initially the technique was used on nine volunteers who were inpatients of the
Gastrointestinal Ward. 50mls of PEG+E (Klean-Prep, Norgine, UK) was instilled into
the rectum using a rectal catheter. After 15 minutes the fluid was aspirated from the
rectum and processed in the same way as WGLF. Fluid was retrieved from three of
the nine patients.
In order to improve the technique I attempted to occlude the upper rectum with a
balloon in order to prevent the loss of fluid proximally. Initially I attempted to use a
urinary catheter with an integral balloon inserted through a disposable sigmoidoscope
or proctoscope, but found the catheter was too flexible and could not be advanced
easily. I therefore used a 12F Nelaton urinary catheter (Pennine) with a condom
attached to the end using surgical suture. This could be advanced through a
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disposable proctoscope and inflated with 40 mis of water. Fluid was easily retrieved
from a further two volunteers.
The samples from the five volunteers were analysed for haemoglobin, albumin, a-1-
antitrypsin and total IgG and the results shown in table 7.1. The assays used for the
measurement of these proteins have been specifically designed for use in WGLF
which has passed through 4m of gut with a perfusion rate of approximately 20 mls/min.
Using the rectal wash technique the fluid is in contact with only 10 cm of gut. In order
to calculate a rough estimate of what could be expected in rectal wash fluid one has to
assume that the rectum will produce proteins at the same rate per cm as the rest of
the gut. The amount of a protein produced by the whole gut per minute can be
approximated by multiplying the normal range by the perfusion rate and in rectal wash
fluid one would expect to see only one fortieth of the amount produced by the whole
gut every minute. The amounts of each protein expected to be seen in 50mls of fluid
held in the rectum for 15 minutes are shown in table 7.2.
Patient Diagnosis Hb (pg/ml) Alb (pg/ml) a-1-AT (pg/ml) IgG (ng/ml)
KD Pancreatic
carcinoma
1 10 1 6
MC Weight loss 36 13 4 1
AT Gastric ulcer,
alcoholism
44 312 34 75
EK Ulcerative
colitis
55 212 28 175
MC Ulcerative
colitis
519 472 38 80
Table 7.1: Results of analysis of rectal wash fluid from five patient volunteers for
haemoglobin (Hb), albumin (alb), alpha-1 -antitrypsin (a-1-AT) and total IgG
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Protein Normal range in Amount expected in 50mls for





Table 7.2: Expected levels of albumin, a-1-antitrypsin and IgG in rectal wash fluid
compared to normal ranges seen in WGLF
In three of the five cases high concentrations of proteins were found, suggesting
exudation from the plasma. The haemoglobin was very variable and raised the
possibility of bleeding due to trauma. I went on to see if changes could be induced by
exposing the rectal mucosa to gluten in susceptible individuals.
Patient Groups
I aimed to examine changes in the rectal wash induced by gluten in patients with
classical coeliac disease and compare them to a control group, namely patients with
irritable bowel syndrome. I then planned to go on to perform the test on patients with a
high likelihood of having low grade pathology coeliac disease such as those with a
raised I EL count or those who had commenced a gluten free diet before investigations
could be undertaken and had clinically responded. 20 patients attending the
Gastroenterology outpatient clinic volunteered to undergo rectal gluten challenge.
They were divided into four diagnostic groups which are detailed in table 7.3.
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Diagnostic Group Number of Patients
Coeliac disease 6
Non coeliac 5
Empirical GFD with response 5
Raised IEL count 4
Table 7.3: Number of patients in each diagnostic group undergoing rectal gluten
challenge
Rectal Gluten Challenge Test
Aliquots of 100 mis of Klean-Prep were stored at -20°C and a fresh aliquot defrosted
prior to each test. Patients were give a bisacodyl suppository to use in the morning
before the test to ensure the rectum was empty.
With the patient lying on their left side, the balloon was inserted into the upper rectum
with the aid of a disposable proctoscope. The balloon was then filled with 40 mis of
water in order to occlude the upper rectum. A rectal catheter was inserted below the
balloon and 50mls of PEG+E instilled into the rectum. The rectal catheter was then
withdrawn and the fluid left in situ for 15 minutes.
After the allotted time, the rectal catheter was re-inserted and as much fluid withdrawn
as possible. The most effective method for withdrawing the fluid was simple drainage
since aspiration caused occlusion of the catheter "eyes" with rectal mucosa. Following
withdrawal of the fluid, the rectal balloon was also removed and the fluid processed
and stored as whole gut lavage fluid. This sample was referred to as the "Baseline
rectal wash".
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On a second day the patient attended after a further bisacodyl suppository and on this
occasion a gluten enema was given. This consisted of 10g crude gluten (Sigma
Chemical Co Ltd, UK) in 40 mis of sterile 0.9% saline and was inserted using a rectal
catheter. The patient was asked to retain the enema for as long as possible and to re-
attend six hours later.
After six hours the rectal wash was repeated and the sample referred to as the
"Challenge rectal wash".
Technical Results
The procedure was tolerated well in all patients. With the exception of one woman in
the empirical diet group who experienced flushing, abdominal discomfort and urgency
of defaecation, no clinical symptoms were induced by the rectal gluten challenge. Two
patients were noted to bleed slightly from haemorrhoids following insertion of the rectal
catheter.
Fluid was retrieved in all patients, but in varying quantities. The volumes retrieved in
each patient are shown in table 7.4. In order to allow for filtration and processing of
the sample, a minimum volume of 10 mis was required. If sufficient fluid was not
retrieved then the sample was diluted with PEG+E to the minimum volume and this
dilution factor was taken into account in all the analyses.
To ensure that the composition of the fluid retrieved was in keeping with PEG+E plus
secretions from the rectal mucosa, I measured the concentration of PEG in the
samples. A known concentration of PEG was instilled in the rectum in the form of
Klean-Prep (59g/l PEG) and so comparing the concentration of PEG in the sample to
this value should enable a calculation of how much of the fluid was secreted by the
rectal mucosa.
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Patient Baseline vol (mis) Dilution Challenge vol (mis) Dilution
1 15 None 2 1:8
2 15 None 10 None
3 10 None 10 None
4 15 None 20 None
5 10 None 20 None
6 2 1:5 2 1:5
7 1 1:10 12 None
8 5 1:2 1 1:10
9 10 None 2.5 1:4
10 2.5 1:4 10 None
11 2.5 1:4 3 1:3
12 15 None 1 1:10
13 5 1:2 1 1:10
14 15 None 15 None
15 15 None 15 None
16 2.5 1:4 5 1:2
17 5 1:3 15 None
18 30 None 5 1:2
19 2.5 1:4 5 1:2
20 1 1:10 0.5 1:10
21 30 None 4 1:3
22 1 1:10 2 1:5
23 20 None 20 None
24 15 None 20 None
Table 7.4: Volume of rectal wash fluid retrieved from each patient at baseline and
challenge and dilution of fluid prior to processing
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Measurement of the Concentration of Polyethylene Glycol in the Samples
The concentration of PEG in the rectal wash fluid was determined using the method
described in Chapter 2. Filtered/processed fluid was used as more aliquots of this
type of sample were available. I tested 18 samples; six paired baseline and challenge
samples from the coeliac group, and two paired samples from each of the non-coeliac,
increased IEL and empirical diet groups. PEG was used as the standard and a
standard curve plotted with the sample values extrapolated from this curve. Klean-
Prep was used as a quality control, and contains a concentration of PEG of 59g/l. The
dilutional effect of processing the rectal wash fluid was taken into account by
multiplying the result by a factor of 1.252. As not all the fluid instilled into the rectum
was retrieved it is not possible to calculate the volume of secretions produced by the
rectum. One can, however calculate the proportion of PEG in the final sample and
therefore the proportion assumed to be produced by the rectum.
The results of this analysis are shown in table 7.5. From the paired data there was no
suggestion of the amount of fluid secreted by the rectum in the baseline test differing
from that secreted in the challenge test.
The concentration of PEG in samples A and B (marked * and + respectively) are
obviously out of keeping with the rest of the samples. In the case of sample A, only a
tiny amount of fluid was retrieved (0.5ml) and, as the concentration of PEG was so
high, I felt this represented Klean-Prep from within the rectal catheter rather than fluid
which had been in contact with the rectal mucosa. Sample B was another small
volume sample (1 ml). The concentration of PEG in this sample was extremely low
and I am unable to explain this. As the PEG concentration in each of these samples is
so different from the rest I felt these were technically unsatisfactory samples and so
excluded them from further analysis.
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Group Sample PEG cone (g/l) Percentage of sample assumed to












Non-Coeliac B 58 2%
C 43 27%
Empirical Diet B 55 7%
C 48 19%
Increased IEL B 46 22%
C 58 2%
Table 7.5: PEG concentration in 18 rectal wash samples. B=baseline sample,
C=challenge sample. Samples A and B are marked by * and + respectively
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Measurement of Albumin, Haemoglobin, Alpha-1-Antitrypsin and IgG
The amount of blood in the fluid was established by assaying haemoglobin and the
amount of plasma or extracellular fluid exudate by the measurement of three proteins;
albumin, a-1-antitrypsin and IgG. These assays were performed by Mr John Bode and
Mr Kenneth Humphreys. The results for the coeliac and non coeliac groups are shown
in figures 7.1-7.3, with the coeliac disease group divided into treated and untreated
patients. It was evident that the amount of haemoglobin in the sample could be
dramatically influenced by local trauma caused by the insertion of the rectal catheter
and therefore did not reflect inflammatory change within the rectal mucosa.
The levels of the three proteins at baseline did not differ between the two groups, and
disappointingly no change was seen after gluten challenge in the coeliac group.
Clearly, the aim of my original plan failed and I was unable to use these proteins to
detect changes in the rectal secretions of coeliacs in response to gluten. These rectal
challenges did, however provide material enabling examination of other potentially
valuable parameters of gut immunology such as IgA and IgM, IgA endomysium































































Figure 7.3: IgG in rectal wash fluid in the coeliac and non-coeliac groups
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Total IgA and IgM in Rectal Wash Fluid
I went on to measure total IgA and IgM in the fluid using the ELISA method detailed in
chapter 2. For the IgA assay, the samples were first diluted to 1:100 before applying
to the plate and for the IgM assay, a 1:5 dilution was initially used. Any samples with
titres above the highest standard were further diluted accordingly. No aliquots of the
fluid were available for three of the samples. As no changes were seen in response to
gluten in the three proteins assayed initially the baseline and challenge samples were
grouped together for data analysis of the IgA and IgM assays (figures 7.4 and 7.5).
Using the Mann-Whitney Test the IgA and IgM levels in the samples from each group
were compared. There were no significant differences between the IgM levels in each
group. The IgA in the untreated coeliac group was, however, significantly different to
each of the other groups; treated coeliacs (p=0.037), non coeliacs (p=0.002), the
raised IEL group (p=0.004) and empirical diet group (p=0.003). The levels in the
treated coeliac group were not different from those in the other groups. The high
levels of total IgA in the five samples from three untreated coeliacs is noteworthy and




































C-GFD Non coeliac Inc IEL Emp GFD
Figures 7.4 and 7.5: Total IgA and IgM in rectal wash fluid in the four patient groups.
C-ND = Untreated coeliacs, C-GFD = Treated coeliacs, Inc IEL = Raised IEL group,
Emp GFD = Empirical diet group
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IgA Endomysium Antibody in Rectal Wash Fluid
As a result of finding IgA endomysium antibody in WGLF from coeliac patients I went
on to examine the rectal wash fluid for the antibody. If the antibody is, indeed, formed
in response to gluten induced gut damage, I wondered, therefore if it could be found in
the baseline rectal wash of coeliac patients in response to reaction of the rectal
mucosa to gliadin peptides in the faecal stream. Of even greater importance, I wanted
to see if local challenging of the rectal mucosa could stimulate antibody production.
I tested a total of 25 rectal wash samples for IgA endomysium antibody. These were
four paired baseline and challenge samples from the coeliac group, two from the non-
coeliac group, two from the empirical diet group and one from the increased IEL group.
The corresponding pairs for the remaining seven samples had all been used up in
previous assays and so were unavailable for this measurement. The assay was
performed using the method described for WGLF in chapter 4, ie the fluid was applied
to the section of umbilical cord without dilution.
With the exception of one sample, all were negative for IgA EmA. The positive result
was found in the challenge sample from a woman with coeliac disease on a gluten
free diet. The change from a negative assay on the baseline sample to the presence
of IgA EmA in the challenge sample is of great interest, as it suggests this
autoantibody is produced in response to local exposure to antigen and by the mucosa
in contact with the antigen, rather than by a systemic response. This finding highlights
the real need for an ELISA assay to measure endomysium antibody.
Cytokine Measurement in Rectal Wash Fluid
Proinflammatory cytokines are thought to play an important role in the pathogenesis of
the mucosal damage seen in untreated coeliac disease. Several studies have shown
increased numbers of lamina propria cells secreting interleukin-2 (IL-2), interleukin-6
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(IL-6) and Tumour Necrosis Factor-a (TNF-a) in both untreated coeliac disease and a
few hours after gluten challenge in treated patients (Przemioslo et al, 1994; Kontakou
et al, 1995b; Breese et al, 1994; Jones et al, 1993; Kontakou et al, 1995a). In
addition, DQ2 restricted T cell clones have been found to secrete IL-4, IL-5, IL-6 and
IL-10 (Nilsen et al, 1995). When planning the study I felt it would be important to see if
proinflammatory cytokines were present in the rectal wash fluid of the coeliac patients
and how their levels compared to the non-coeliac group. Dr Andrea Lear and Mrs
Hazel Drummond performed IL-6 and TNF-a ELISAs on these samples. IL-1 has
many functions including the induction of IL-6 secretion and is thought to play an
important role in the disease process of inflammatory bowel disease (IBD), as is IL-8
which has a chemotactic effect on both T and B cells. As both IL-1 p and IL-8 were
being measured in WGLF from patients with IBD and controls, the rectal wash
samples were also tested for these cytokines.
The results of cytokine analysis in rectal wash fluid is shown in table 7.6. IL-1 p and IL-
8 were each measured in 44 of the 45 samples. There was insufficient fluid for both
assays in two samples. IL-6 was measured in 32 of the 45 samples, again due to lack
of fluid in 13 samples. TNF-a was measured in a total of 17 samples and was
detectable in only one of these, a challenge sample from a patient in the empirical diet
group. In view of the shortage of sample material and the failure to detect this
cytokine in the vast majority of samples tested, no further analysis of TNF-a was
performed in the fluid. Wherever possible the cytokine analysis was repeated at
differing dilutions in order to achieve an absolute concentration, but if sample material
was in short supply, the value was expressed as greater than the top standard.
There was no difference in IL-1 p measured in baseline and challenge samples in
either group. The levels in each group were therefore compared (figure 7.6). There
was no significant difference between the untreated coeliacs and any other group, but
the treated group were significantly different from the three colitics (p=0.036).
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Group Sample IL-1B (pa/ml) IL-6 (pg/ml) IL-8 (pg/ml)
Colitis B >600 No sample >1000
B 180 No samole >1000
B 102 90 >1000
Emp Diet B 6 70 6
C 37 No sample No sample
B 7 6 234
C 164 74 >1000
B 600 57 >1000
C 36 22 898
B 2 0 38
C 0 0 14
B 68 92 2593
C 17 10 2406
Inc IEL B 15 No sample 95
C 42 No samole 608
B 234 19 167
C 21 92 0
B No sample 19 307
C 298 574 6314
B 13 21 316
C 8 0 211
Non Coeliac B 0 No sample 20
B 0 0 799
C 265 9 >1000
B 22 No sample 497
B 335 162 >1000
C 111 38 >500
B 0 0 16
C 0 0 13
B 40 No sample 1347
C 15 No sample 289
B 5 No sample 859
B 6 0 267
C 4 11 109
Coeliac (GFD1 B 16 4 83
C 19 3 384
B 14 0 57
C 14 0 49
Coeliac CNDt B 18 13 >1000
C 7 No sample 65
B 108 101 5966
B 411 >500 >1000
C 750 456 >1000
B 555 No sample >1000
C 7 No samole 68

















C-ND C-GFD Non coeliac Inc IEL Emp diet Colitis
Figure 7.6: Levels of IL-1 p present in rectal wash fluid in different diagnostic groups.
The treated coeliac group (C-GFD) was significantly different from the colitis group
(p=0.036)
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One of the functions of IL-6 is to stimulate secretion of IgA by plasma cells. In view of
the interesting results in the IgA assay, I compared these results to the levels of IL-6 in
the same samples (figure 7.7). There was, however no correlation between the two




















Figure 7.7: Comparison of IL-6 and IgA in 28 rectal wash samples
Wide variation can be seen in the IL-8 levels in rectal wash fluid in all the groups.
Although the paired baseline and challenge data looked promising, when analysed no
differences were found between the groups, with the exception of the baseline
samples in the untreated coeliac and the possible coeliac group (made up of the
combined raised IEL and empirical diet groups) (p<0.05). This is very likely to be due
to the extremely small number of samples in the untreated group. The paired pre- and




































Gluten challenging is required to confirm the diagnosis of coeliac disease in a minority
of patients. Oral gluten challenging, however, is often time-consuming and may
induce distressing clinical symptoms in some patients. Other patients do not develop
symptoms, leaving a dilemma as to when to perform small bowel biopsy. The finding
of a histologically normal small bowel also produces confusion as to whether this truly
reflects a negative gluten challenge, or simply that relapse has not yet occurred. For
these reasons, an alternative method for gluten challenging is needed and the positive
results from other centres suggests rectal gluten challenge may be the way forward.
In order for this to take place, the technique employed must be simple to perform as
well as reliable in its results. I attempted to use a technique of rectal washing,
avoiding the need for multiple rectal biopsies and expert histological analysis.
Although the tests performed on the fluid were multiple and appear complex, each
individual assay is simple to perform and could be adopted by most motivated
laboratories. Unfortunately, I was unable to demonstrate any clear difference between
the coeliac and non-coeliac groups in any parameter measured and the responses to
gluten were wide and varied with no significant difference between the groups. This
may be due to the small size of each group, which reflected the difficulty I experienced
in recruiting volunteers for this study. Many of the patients who did volunteer did so
because their diagnosis was not clear-cut, and so would be the patients in whom a
reliable and accurate rectal gluten challenge would be the most useful. Many had
commenced a low-gluten or gluten free diet at home before attending the outpatient
clinic and had experienced a clinical response. Their investigations were either normal
or equivocal reflecting either an effect of their diet or an alternative diagnosis to coeliac
disease. The patients in the increased IEL group could not be definitively diagnosed
as gluten sensitive and so could not be included in the coeliac group.
This work did produce interesting results aside from the effect of local instillation of
gluten. Although it is impossible to directly compare the levels of proteins found in
rectal wash fluid to WGLF as the samples are collected in different ways and are
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designed to measure different sections of the gut, I was surprised by the often
extremely high levels of proteins found. I initially thought that the high levels seen in
the patients with active proctitis must reflect acute inflammation, but was surprised to
see similar levels in individuals with normal rectal mucosa. As I have already
mentioned, WGLF has passed through the whole gut prior to collection whereas the
rectal wash fluid was in contact with approximately 10 cm of mucosa before retrieval.
One possible explanation would be a difference in perfusion rates, but this did not
seem to be the cause as the levels were often higher than the predicted ranges for the
proteins which were calculated, albeit with a great deal of assumption. Another
explanation would be an artificially low recovery of protein in WGLF due to digestion or
degradation in the gut during the test. This is known to be the case for albumin but not
for a-1-antitrypsin or IgG.
Another surprising finding was the variable volume of fluid retrieved. In no patient was
the initial volume of 50mls retrieved. In the beginning, I felt this was due to proximal
loss and this led to the development of the proximal balloon technique. Despite this,
however, in many patients only extremely small volumes could be recovered. In many,
fluid did not immediately flow from the rectal catheter on reinsertion and this could be
rectified by manipulating the tip of the catheter anterolateral^. In some patients,
however, no manoeuvre resulted in increased volumes being retrieved. As none of
the patients experienced incontinence during the test, the fluid must have been lost
proximally despite the placement of the balloon. Other centres have used
commercially manufactured silastic multiple lumen tubes to perform perfusion studies
in patients with inflammatory bowel disease and I attempted to purchase one of these
to see if the technique could be improved, but unfortunately these are custom-made at
very high cost and so were unavailable to me. In the future, however, this would be
worth investigating to see if this technique can be taken further as a minimally invasive
method of investigating rectal inflammation.
The results of the cytokine assays were very interesting. High levels of IL-8 were seen
in many of the patients, including the non-coeliac group. Again this may reflect the
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difference in perfusion between the two techniques. Detecting IL-6 at all was a great
surprise when it had been completely undetectable in WGLF and this led to a set of
interesting experiments revealing the immediate disappearance of IL-6 in filtered
WGLF. We felt this may reflect the binding of the cytokine to soluble receptors
present in the fluid.
Although it was a great disappointment to me that this technique did not provide a
method for performing rectal gluten challenging, I feel overall that the work has had
positive results of interest both to myself and to colleagues within our Unit.
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CHAPTER 8: GENERAL DISCUSSION
Gluten sensitive enteropathy is a condition comprising a broad spectrum of both
mucosal pathology and clinical symptoms. In this thesis I have presented work relating
to three aspects of the condition with the aim of augmenting the diagnostic process in
patients with minimal changes in small bowel biopsy pathology or in whom the
diagnosis of coeliac disease is not clear-cut.
In coeliac disease, an infiltration of small intestinal intraepithelial lymphocytes occurs
and, increasingly, individuals are being identified with normal mucosal architecture but
raised IEL counts. Many of these patients have dramatic symptoms which respond to
exclusion of gluten from the diet. I have presented work describing the development
of a technique to quantify IEL according to the epithelial surface length using
computerised image analysis to replace our traditional technique of counts of epithelial
cells and IEL by light microscopy. The computerised technique has been validated by
comparison of counts performed on a group of small intestinal biopsies using both
methods, counts obtained by two independent observers from the same sections,
counts in multiple biopsies taken on the same occasion, and by counting IEL in two
sections taken 100pm apart from a single large jejunal biopsy. In all of these
experiments, my computerised technique has been shown to be both reliable and
reproducible and, on the basis of this work, has now been adopted by our laboratory
as the routine method for performing IEL counts on patient samples.
I used the technique to perform counts on 250 small bowel biopsies with normal
mucosal architecture. I found IEL counts of over 50 cells/mm in 30 of these, seven
from known treated coeliacs and the remainder from individuals with various clinical
symptoms in whom coeliac disease was considered to be a possible underlying cause.
On the basis of these raised IEL counts, the possibility of low grade pathology coeliac
disease was discussed with the patients and nine of the 23 agreed to exclude dietary
gluten for a trial period. A clinical response was seen in all but one supporting this
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diagnosis. These results are in keeping with similar findings from my predecessor, Dr
Eduardo Arranz.
Although counts of total, CD3+ and y8+ IEL are extremely useful in the diagnosis of
both classical and low grade pathology coeliac disease, we are still unclear as to the
function of these cells and their role in the development of enteropathy. They do
demonstrate some cytotoxic abilities, especially against targets coated with
enterotoxins, and they produce cytokines possibly as protection against viral or
bacterial infection. It is also thought that they play a role in the development of oral
tolerance to ingested antigens, and this mechanism may be abnormal in coeliac
disease. IEL infiltration may therefore be a local T-cell-dependent response to an
ingested antigen, and indeed the counts of total and CD3+IEL do fall on withdrawal of
dietary gluten in gluten sensitive individuals. Despite this, however, the IEL infiltration,
per se, does not seem to damage the mucosa as demonstrated by the occurrence of
infiltration in otherwise normal biopsies. Another dilemma is the apparent failure of y5+
IEL to return to normal levels despite treatment with a gluten free diet for several
years. It may be that counts fall very gradually and reduction to normal levels takes
many years.
Over the next few years, work in this field should be aimed at the identification of the
role played by these cells in the development of gluten sensitive enteropathy and also
at the ability of coeliac individuals to develop oral tolerance to dietary antigens, which
can be achieved by using a novel protein such as keyhole limpet haemocyanin. If
these aspects of the disease are understood more fully, it may be possible to develop
alternative treatment strategies for those in whom lifelong dietary exclusion is not
sufficient to induce remission of the enteropathy, and for patients who are unable to
comply with diet treatment recommendations.
In the course of my work I, along with Mr Bode, have established the IgA endomysium
antibody assay using indirect immunofluorescence with human umbilical cord as the
immunogenic substrate. Since the description of this technique by Ladinser et al in
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1994 it has been rapidly adopted throughout the world making the measurement of
this sensitive and specific coeliac related antibody widely available. We have
validated our method by initially testing stored serum samples from coeliac and non-
coeliac patients and then by prospectively testing serum submitted to the laboratory for
analysis of IgA antigliadin antibody. Our assay shows a sensitivity of 100% and
specificity of 94.6% and is now established in the laboratory's NHS analytical service.
In the light of the positive response of eight patients with raised IEL counts to gluten
free diet, I measured IgA EmA in stored serum samples from 20 of the 23 with raised
counts. Three of the eight responders did demonstrate the antibody in their serum,
and none of the patients with self-limiting illness had positive tests. Testing the
antibody in these patients is therefore useful as, although a negative result does not
exclude a response to gluten withdrawal, a positive result suggests that the biopsy
findings do reflect low grade pathology gluten sensitivity and a clinical improvement
will be seen following the commencement of a gluten free diet.
The positive predictive value of IgA endomysium antibody for coeliac disease has led
to its use in the identification of undiagnosed cases in high risk populations, such as
individuals with type I diabetes or Down's Syndrome and in first degree relatives of
coeliacs. We have looked at a large number of insulin-dependent diabetics; more than
600 adults and over 130 children. We found 18 patients with positive IgA EmA and
offered each of them the chance to discuss the implications of this result. I was
surprised to find that of the 17 who attended the outpatient clinic, 70% had symptoms
which could be attributed to coeliac disease. 70% also had haematological or
biochemical abnormalities, the commonest being hypomagnesaemia, which was seen
in ten of the patients. At the time of submission of this thesis only four patients have
had small bowel biopsies taken. All of these patients had severe symptoms,
predominantly diarrhoea, and I have been surprised to see, therefore, that only one
patient had classical villous atrophy and crypt hyperplasia and two patients had normal
IEL counts. It may be that the immune response in diabetes is different to that of non-
diabetic individuals and that mucosal damage is mediated predominantly by
complement activation. Alternatively, the mucosal lesion may be very patchy and the
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duodenal biopsies may have been taken from areas proximal to affected gut. These
four patients have been offered treatment with a gluten free diet with subsequent
improvement in their symptoms.
As a result of the positive findings of this study I feel that all patients with type I
diabetes should be offered serological screening for coeliac disease using IgA EmA
and antigliadin antibodies.
In order to assess the prevalence of coeliac disease in a hospital population rather
than in healthy volunteers or blood donors, we tested for IgA EmA and AGA in 300
plasma samples submitted for full blood count assessment and 600 stored serum
samples from patients attending our own unit with gastrointestinal symptoms. We
found 27 samples positive for both antibodies; eight were known to have coeliac
disease, one had dermatitis herpetiformis, and five had alcoholic liver disease. Two
patients agreed to undergo endoscopic biopsy, of which one confirmed coeliac
disease and the other is still outstanding.
Although this study only revealed one new case of coeliac disease it led to the
investigation of chronic liver disease as a cause of a false positive result in the
endomysium antibody assay. This work revealed an atypical fluorescent staining
pattern produced against human umbilical cord by serum from individuals with
cirrhosis. I also found high levels of total IgA in these patients and high titres of IgA
AGA.
In the future I think that screening for coeliac disease will become more common,
especially in the diabetic population and because of this I took earlier work by my
colleagues further by developing a method for measuring IgA EmA in material eluted
from dried blood spots. This work looks extremely promising, as does my
predecessors' work with antigliadin antibodies from eluted spots. The assays
obviously require more work on their development and validation but I am sure they
will prove to be valuable tools in screening for coeliac disease.
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As selective IgA deficiency is associated with gluten sensitive enteropathy, relying on
IgA antibodies to detect coeliac disease will lead to missed diagnoses and delayed
treatment. In view of this, I modified the IgA EmA assay to detect the IgG isotype of
the antibody and initially tested a woman with dysimmunoglobulinaemia and jejunal
subtotal villous atrophy which was refractory to gluten free diet. The IgG antibody was
positive and became negative following her clinical response to immunosuppressive
treatment with cyclosporin. I have since found IgG EmA in serum from seven further
IgA deficient patients, all of whom have now been diagnosed with coeliac disease.
In order to assess the prevalence of IgG EmA in patients with coeliac disease and
normal total IgA levels I tested 38 IgA EmA positive serum samples for the IgG isotype
and found both classes of antibody present in 18%. This figure is in keeping with
results from another group.
The modification of the IgA assay has, therefore, proved to be a useful tool for
detecting coeliac disease in IgA deficient individuals. We have only been able to test
a small number of patients as we have used only diagnostic samples sent in to our
routine analytical service. To my knowledge, there have been no large studies to
assess the prevalence of IgG EmA in IgA deficient coeliacs and I think this would be
extremely valuable to perform, but it will require collaboration between several centres
in order to increase the number of samples available.
The site of production of endomysium antibodies and the nature of the antigen against
which they are directed are, as yet, unknown. The finding of tissue antibodies in
intestinal secretions, and more recently in whole gut lavage fluid, may reflect either
mucosal production or spill-over from a systemic origin. I examined stored WGLF and
serum from a group of coeliacs and found IgA EmA in the fluid in three patients, one of
whom was on a gluten free diet and did not demonstrate the antibody in serum. This
would therefore suggest that the antibody is produced by the mucosal plasma cells
and at high titres spills over into the systemic circulation.
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The function of this antibody is unknown at the present time. It may represent an
autoantibody which causes the mucosal lesion seen in coeliac disease but,
alternatively it may be produced secondarily after T-cell activation has induced
mucosal damage. Obviously work in the future will be directed towards the
identification of the antigen which will enable the development of quantitative assays in
the form of ELISAs. Having an accurate objective measurement of antibody titres will
help the understanding of the relationship between this antibody and the natural
history of the disease. Our laboratory's expertise in the technique of whole gut lavage
offers an ideal opportunity to further examine this material for endomysium antibody in
order to establish its function and source.
Other groups have investigated changes in rectal mucosal histology in response to
local exposure to gluten and have suggested that this method of gluten challenging
could, in the future, replace oral gluten challenging. The changes induced are very
rapid, the majority being maximal at 6 hours, and the results appear reproducible. The
histological changes are subtle, however, and require expertise and computerised
image analysis to detect them. The interpretation of changes is also difficult and this
may account for the majority of studies being carried out in only one or two centres.
I investigated the possibility of analysing changes induced in the rectal mucosa by
local gluten exposure using a rectal wash technique. I felt this would be less invasive
than performing multiple rectal biopsies on several occasions. I devised a technique
for instilling PEG+E into the rectum and then retrieving the fluid after a period of time.
The fluid was then processed and analysed in the same way as WGLF. I hoped that,
if changes in mucosal permeability could be induced in sensitive individuals, increased
exudation of proteins such as albumin, a-1-antitrypsin, and immunoglobulins could be
detected in the fluid.
Unfortunately this theory was not borne out by the results. There was a great deal of
variability in the concentration of PEG in the fluid retrieved from different patients,
suggesting different amounts of fluid secreted by the rectal mucosa. There was no
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consistency within groups and so I could not say that one group was more likely to
produce higher volumes of rectal secretions in response to gluten challenge than
another. I also found that the volume of fluid retrieved after the test varied from
patient to patient and also between baseline and challenge tests in the same patient.
In no patient was the instilled volume of 50mls retrieved. Occlusion of the upper
rectum did not improve this and I presume that proximal leakage of the fluid occurred
despite the placement of an inflated balloon. There was no significant difference in
the albumin, a-1-antitrypsin or IgG at baseline between the groups and, more
importantly, no significant difference following challenge either.
I went on to examine other parameters in the fluid including total IgA and IgM, and
found that levels in the fluid from untreated coeliacs was significantly higher than those
in treated coeliacs, non coeliacs, individuals with increased IEL and those treated
empirically with gluten free diet. There were no differences in IgM levels between any
of the groups.
In the light of the finding of IgA endomysium antibody in WGLF from coeliacs, I
examined the rectal wash fluid for this antibody. Out of a total of 25 samples IgA EmA
was found in only one, a post-challenge sample from a treated coeliac. Again, this
supports the concept of mucosal production of the antibody.
We went on to examine the fluid for pro-inflammatory cytokines and I was surprised by
the number of samples found to contain high levels of IL-1 p, IL-6 and IL-8. Again, no
significant difference was found between the levels detected in each group. One of
the functions of IL-6 is to stimulate production of IgA by plasma cells, but there was no
correlation between the IL-6 levels and total IgA in the fluid.
For this work I instilled gluten into the rectum and performed the rectal wash technique
six hours later. This period of time was chosen on the basis of reports of maximal
histological changes occurring at six hours post-challenge. It may be that this period
of time is not long enough to induce exudation of proteins from the plasma and
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performing the rectal wash after, say 24 hours may produce different results. This
may also be the case for IgA EmA and a longer challenge may produce positive
assays in more of the samples.
My technique for performing the rectal wash was not ideal and I would probably have
had greater success if I had used a custom-made catheter. If this work is continued,
then a manufactured all-in-one double balloon perfusion catheter should be used. The
time period between the gluten challenge and the test should also be adjusted to see
if changes can be induced in gluten sensitive individuals. If changes can be induced,
the test should also be performed after challenge with another dietary antigen such as
p-lactoglobulin or ovalbumin in order to show that the changes are specific to gluten.
Although rectal gluten challenging has offered promise as an adjunct to the diagnosis
of coeliac disease, with the advent of the endomysium antibody assay we may find
that it is never developed for clinical use but will remain as a research based method.
Over the next few years I am sure we will see dramatic developments in the
understanding of the pathogenesis of coeliac disease and also in the diagnostic
criteria used for the condition. Already, jejunal biopsy by peroral capsule is being
superseded by endoscopic distal duodenal biopsy using large cupped, spiked biopsy
forceps. This technique is safe, rapid and can be performed using either local
anaesthetic throat spray or sedation, making it acceptable to the patient. Using the
specifically designed forceps enables the collection of large, multiple biopsies which
are perfectly adequate for a histological diagnosis to be made.
The advent of a widely available assay for measuring IgA EmA has already changed
our approach to the investigation of patients with diarrhoea, weight loss or anaemia.
Previously, patients with such symptoms would have had a series of invasive
investigations including small bowel biopsy, performed as a matter of routine, but now
serum antigliadin and endomysium antibodies are checked as first line investigations
before biopsy is embarked upon.
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The accuracy of endomysium assays, throughout the world, is now so good that the
need for performing small bowel biopsies in symptomatic, antibody positive individuals
is being questioned. In my own work in the diabetic patients, three of the biopsies
have been either entirely normal or very mildly abnormal, but despite this the patients'
symptoms have improved on a gluten free diet. In these patients, therefore, the
decision to treat the patients has been based on the endomysium antibody result
anyway, with little being added by the biopsy.
Another change to the diagnostic criteria will be the inclusion of the presence of HLA-
DQ2. I am sure we will find in a few years that individuals will be diagnosed as gluten
sensitive on the basis of symptoms, a positive endomysium antibody, their HLA type
and their clinical response to a gluten free diet.
Over the next few years I hope that work in coeliac disease in Edinburgh will continue
in the following areas:
• Assessment of oral tolerance to novel dietary antigens in coeliacs compared to
normals
• Assessment of the prevalence of IgG EmA in IgA deficient coeliacs
• Measurement of IgA EmA in WGLF from treated and non treated individuals
• The development of a quantitative ELISA for IgA EmA when the endomysium
antigen is identified
• Further assessment of cytokine levels in both rectal wash fluid and WGLF from
coeliacs compared to non coeliacs and those with inflammatory bowel disease
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ALBUMIN IN WHOLE GUT LAVAGE FLUID
PRINCIPLE OF METHOD
When human albumin to be assayed reacts with its specific antibody, precipitating
immunocomplexes are quickly formed in the presence of polyethylene glycol. If the
antibody is present in large excess, these precipitates produce a turbidity which is
related to the concentration of albumin in the sample. The turbidity is
photometrically measured at the wavelength 340nm. Absorbance readings
obtained by assaying calibration standards are used to generate a standard curve,
from which the concentration of albumin in the sample is derived.
REFERENCES
Brydon WG, Choudari CP, Ferguson A. Relative specificity for active inflammatory
bowel diseaseof plasma derived proteins in gut lavage fluid. Eur J. of Gastro. and
Hepatol. 1993; 5: 269-273.
HAZARDOUS SUBSTANCES AND NATURE OF HAZARD
CHEMICAL
sodium azide: toxic - see COSSH form no 107
phenyl methyl sulphonyl fluoride: toxic - see COSSH form no 104.
BIOLOGICAL
Whole gut lavage fluid (WGLF) is potentially infectious and should be handled
appropriately. Procedures for cleaning glassware and disposal of tips which have
come in contact with these materials should be strictly adhered to.
PRECAUTIONS
Safety measures as detailed in the Departmental safety handbook must be
followed. Appropriate COSHH forms should be read and understood before
undertaking this assay.
SPECIMEN REQUIREMENTS
WGLF: 6 x 1.5 ml samples of whole gut lavage fluid (filtered and processed)
should be aliquoted into 2 ml microtubes with screw lids (Sarstedt, UK). Samples
should be stored at -70 C. The procedure for filtering and processing lavage fluid is
described below.
1. 2 x 25 ml samples of clear WGLF are collected from the patient and processed
withion 15 minutes where possible. If the collected samples do not appear very
clear or do not filter relatively quickly then centrifuge the samples at 3600 rpm for
5 minutes.
1
2. Filter 10 - 15 ml into a universal container, using Whatman GF/A 12.5 cm filter
paper. Transfer 10 ml to another universal container.
3. Add 1 ml SBTI. Mix.
Add 0.56 ml NaEDTA. Mix.
Add 0.24 ml PMSF . Mix.
Add 0.12 ml sodium azide. Mix.
Leave for 2 minutes.
Add 0.6 ml new born calf serum. Mix, and dispense aliquots.
SAMPLE STORAGE AND STABILITY
samples of lavage should be kept stored at -70. These samples are stable for up to
1 year at least.
INSTRUMENTATION
Turbidity is measured using the PU8640 spectrophotometer (Room 1).
Switch on main power. Side of instrument.
Set to ABS mode
Set wavelength to 340 nm
Set delay to 0.01
Set volume to 0.8
Set Temp Off
Store as program 4
Lavage samples are diluted with PEG reagent using the GILSON DILUGIL V. This
is set to sample 0.05 ml and to dispense 0.95ml.
Assays are carried out using 2 ml polystyrene tubes (LIP Ltd) 64 x 11 mm; code
no 30908.
REAGENTS
All reagents are analar grade and obtained from Merck (BDH) unless otherwise
stated. These are stored in the fridge in room 1 unless otherwise stated.
FOR PROCESSING WGLF
1. Phosphate Buffered Saline: (PBS - Sigma) 1 tablet dissolved in 200 ml distilled
water to give pH 7.2.
2. Soy Bean Trypsin Inhibitor: (SBTI - Sigma):Dissolve 0.1g per 100 ml PBS.
Solid kept at -20 C.
3. Disodium EDTA: Add 11 g to 100 ml distilled water. Dissolve to form a saturated
solution. Store at room temperature. Solid stored in room 1 chemical cupboard.
4.Phenylmethylsulphonylfluoride: (PMSF - Sigma) 0.1 M in 95% alcohol (IMS).
Store solid in room 1 chemical cupboard.
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5. Sodium Azide: 2g/100 ml distilled water.
FOR WGLF ALBUMIN ASSAY
1. PEG Reagent: 40g polyethylene glycol
6000 (biochemical grade), 6g tris, 2g Tween 20 (Sigma), and 1g sodium azide
dissolved in 800 ml distilled water, adjusted to pH 7.0 with dilute hydrochloric acid
and made up to 1 litre volume with distilled water.
2. Anti Human Albumin (sheep): (SAPU - code S034-205). Store frozen in aliquots
of 0.7 ml at -20 C.
3. Antibody Reagent: Dilute sheep anti human albumin serum 1 in 40 with the
PEG reagent on the day of assay.




1. Stndard serum SPS01: (Protein Reference Unit - Sheffield). Keep at 4 C.
2. Albumin: Dilute standard serum with diluent (Reagent 4) to give the following
range of standards : 0,10,20,50,100,200 ug/ml. Prepare fresh on day of assay.
eg for a standard with albumin concentration 40.5 g/l and a1-antitrypsin 1.52 g/l.
Take 100 ul standard and dilute it with 0.66 ml of diluent, to give an a1-antitrypsin
200 ug/ml standard.
Dilute 0.2, 0.1, 0.05, and 0.05ml of this with respectively 0.2, 0.3, 0.45 and 0.95 ml
diluent to give further standards of 100, 50, 20, and 10 ug/ml. To get a series of
albumin standards with similar concentration dilute 37.5 ul of each of the a1-
antitrypsin standards with 1.0 ml diluent.
QUALITY CONTROL MATERIAL
This consists of a lavage sample from a normal volunteer (blood donor) to which
serum from the same volunteer is added to simulate leakage as in inflammatory
bowel disease.
Store in aliquots of 0.5 ml at -70 C. Stable for up to 1 year at this temperature.
ANALYTICAL PROCEDURE
1. Bring PEG and Diluent reagents to room temperature.
2. Blanks : Dilute 50 ul diluent (B1), standards (SB), and test samples (TB), with
0.95 ml PEG reagent in 2 ml polystyrene tubes, in duplicate.
3
3. Tests : Dilute 50 ul diluent (B2), standards (S), and test samples (T), with 0.95
ml Antibody reagent in 2 ml polystyrene tubes, in duplicate.
4. Read Blanks and Tests after 15-20 minutes at 340nm using the
spectrophotometer. Recall programme 4, check volume = 0.8
Zero on PEG reagent. This requires 3-4 aspirations before reading stabilises.
Read correseponding blanks and then tests for each sample; this will tend to
minimise any errors caused by baseline drift.
CALCULATION OF RESULTS
1. Calculate B2 - B1 = OD value for 0 ug/ml albumin
S - SB = OD values for 10 - 200 ug/ml albumin
T - TB = OD values for test samples.
2. Plot a graph of OD 340 values for standards and read test sample results from
this; calculate and report mean values.
ACCEPTANCE OF RESULTS
Repeat analysis within batch gives a coefficient of variation of 6%. Patient results
should only be reported when QC value is +-12% of expected value.
REPORTING FORMAT
Results should be reported to the nearest whole number. Reference range based
on 62 volunteer subjects and patients with no known organic disease is 0 - 26
ug/ml.
CLINICAL SIGNIFICANCE OF RESULTS
Values greater than 26 ug/ml indicate active inflammatory bowel disease.
INTERFERENCES
The assay is specific for the measurement of albumin in lavage. Albumin is
unstable in lavage prior to processing due to presence of proteases in lavage and
variable amounts ranging from 10 - 80% of albumin can be lost within 2 hours at




ALPHA-1-ANTITRYPSIN IN WHOLE GUT LAVAGE FLUID
PRINCIPLE OF METHOD
When human alpha-1-antitrypsin (A1AT) to be assayed reacts with its specific
antibody, precipitating immunocomplexes are quickly formed in the presence of
polyethylene glycol. If the antibody is present in large excess, these precipitates
produce a turbidity which is related to the concentration of albumin in the sample.
The turbidity is photometrically measured at the wavelength 340nm. Absorbance
readings obtained by assaying calibration standards are used to generate a
standard curve, from which the concentration of A1AT in the sample is derived.
REFERENCES
Brydon WG, Choudari CP, and Ferguson A. Relative specificity for active
inflammatory bowel disease of plasma derived proteins in gut lavage fluid. Eur J.
of Gast and Hepatol 1993, 5:269-273.
HAZARDOUS SUBSTANCES AND NATURE OF HAZARD
CHEMICAL
sodium azide: toxic - see COSSH form no 107
phenyl methyl sulphonyl fluoride: toxic - see COSSH form no 104
BIOLOGICAL
Whole gut lavage fluid (WGLF) is potentially infectious and should be handled
appropriately. Procedures for cleaning glassware and disposal of tips which have
come in contact with these materials should be strictly adhered to.
PRECAUTIONS
Safety measures as detailed in the Departmental safety handbook must be
followed. Appropriate COSHH forms should be read and understood before
undertaking this assay.
SPECIMEN REQUIREMENTS
Whole gut lavage fluid: 6 x 1.5 ml samples of whole gut lavage fluid (filtered and
processed) should be aliquoted into 2 ml microtubes with screw lids (Sarstedt, UK).
Samples should be stored at -70 C. The procedure for filtering and processing
lavage fluid is described below.
1. 2 x 25 ml samples of clear lavage fluid are collected from the patient and
processed withion 15 minutes where possible. If the collected samples do not
appear very clear or do not filter relatively quickly then centrifuge the samples at
3600 rpm for 5 minutes.
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2. Filter 10 - 15 ml into a universal container, using Whatman GF/A 12.5 cm filter
paper. Transfer 10 ml to another universal container.
3. Add 1 ml SBTI. Mix.
Add 0.56 ml NaEDTA. Mix.
Add 0.24 ml PMSF . Mix.
Add 0.12 ml sodium azide. Mix.
Leave for 2 minutes.
Add 0.6 ml new born calf serum. Mix, and dispense aliquots.
SAMPLE STORAGE AND STABILITY
samples of lavage should be kept stored at -70. These samples are stable for up to
1 year at least.
Turbidity is measured using the PU8640 spectrophotometer (Room 1).
INSTRUMENTATION
Switch on main power. Side of instrument.
Set to ABS mode
Set wavelength to 340 nm
Set delay to 0.01
Set volume to 0.8
Set Temp Off
Store as program 4.
Lavage samples are diluted with PEG reagent using the GILSON DILUGIL V. This
is set to sample 0.05 ml and to dispense 0.95 ml.
Assays are carried out using 2 ml polystyrene tubes (LIP Ltd) 64 x 11 mm; code
no 30908.
REAGENTS
All reagents are analar grade and obtained from Merck (BDH) unless otherwise
stated. These are stored in the fridge in room 1 unless otherwise stated.
a. FOR PROCESSING WGLF
1. Phosphate Buffered Saline: (PBS - Sigma) 1 tablet dissolved in 200 ml distilled
water to give pH 7.2.
2. Soy Bean Trypsin Inhibitor: (SBTI - Sigma):Dissolve 0.1g per 100 ml PBS.
Solid kept at -20 C.
3. Disodium EDTA: Add 11 g to 100 ml distilled water. Dissolve to form a saturated
solution. Store at room temperature. Solid stored in room 1 chemical cupboard.
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4. Phenylmethylsulphonylfluoride: (PMSF - Sigma) 0.1 M in 95% alcohol (IMS).
Store solid in room 1 chemical cupboard.
5. Sodium Azide: 2g/100 ml distilled water.
b. FOR A1 AT ASSAY
1.PEG reagent: 40g polyethylene glycol 6000 (biochemical grade), 6g tris, 2g
Tween 20 (Sigma), and 1g sodium azide dissolved in 800 ml distilled water,
adjusted to pH 7.0 with dilute hydrochloric acid and made up to 1 litre volume with
distilled water.
2. Anti Human A1AT (goat): (Protein Reference Unit - Sheffield). Store frozen in
aliquots of 0.7 ml at -20 C.
3. Antibody Reagent: Dilute antisera 1 in 40 with the PEG reagent on the day of
assay.




1. Standard Serum SPS01: (Protein Reference Unit - Sheffield). Keep at 4 C.
2. A1 AT standards: Dilute standard serum with Diluent (Reagent 4) to give the
following range of standards : 0,10,20,50,100,200 ug/ml. Prepare fresh on day of
assay.
eg for a standard with A1AT 1.52 g/l. Take 0.1 ml standard and dilute it with 0.66
ml of diluent, to give an a1-antitrypsin 200 ug/ml standard. Dilute 0.2, 0.1, 0.05,
and 0.05 ml of this with respectively 0.2, 0.3, 0.45 and 0.95 ml diluent to give
further standards of 100, 50, 20, and 10 ug/ml.
QUALITY CONTROL
This consists of a WGLF sample from a patient volunteer who has agreed to have
his sample tested for HIV and Hep B status.
Store in aliquots of 0.5 ml at -70 C. Stable for up to 1 year at this temperature.
ANALYTICAL PROCEDURE
1. Bring PEG and Diluent reagents to room temperature.
2. Blanks : Dilute 50 ul diluent (B1), standards (SB), and test samples (TB), with
0.95 ml PEG reagent in 2 ml polystyrene tubes, in duplicate.
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3. Tests : Dilute 50 ul diluent (B2), standards (S), and test samples (T), with 0.95
ml Antibody reagent in 2 ml polystyrene tubes, in duplicate.
4. Read Blanks and Tests after 15 - 20 minutes at 340nm using the
spectrophotometer. Recall programme 4. Zero on PEG reagent. This requires 3 - 4
aspirations before reading stabilises. Read corresponding blanks and then tests for
each sample; this will tend to minimise any errors caused by baseline drift.
CALCULATION OF RESULTS
1. Calculate B2 - B1 = OD value for 0 ug/ml A1 AT
S - SB = OD values for 10 - 200 ug/ml A1 AT
T - TB = OD values for test samples.
2. Plot a graph of OD 340 values for standards and read test sample results from
this. Calculate and report mean values.
ACCEPTANCE OF RESULTS
Repeat analysis within batch gives a coefficient of variation of 11 %. Patient
results should only be reported when QC value is +- 22 % of expected value.
REPORTING FORMAT
Results should be reported to the nearest whole number. Reference range based
on 62 volunteer subjects and patients with no known organic disease is 0 - 19
ug/ml.
CLINICAL SIGNIFICANCE OF RESULTS
Because there is much less A1AT in serum compared with albumin and IgG, it is a
less sensitive marker of leakage in inflammatory bowel disease.
INTERFERENCES
The assay is specific for A1 AT in lavage. A1 AT is stable in lavage for up to 2 hours




HAEMOGLOBIN IN WHOLE GUT LAVAGE FLUID AND FAECES
PRINCIPLE OF METHOD
Haemoglobin is converted to fluorescing porphyrins by the removal of Fe. Total haemoglobin is
determined by reaction with heated oxalic acid:FeS04 reagent which converts haem to
porphyrin without loss of preformed porphyrins. A 3 step purification procedure eliminates other
interfering fluorescent materials which may be present.
REFERENCE
Schwartz S., Dahl J., Ellefson M., Ahlquist D.: Clin Chem: 29 (1983) 2061-2067.
Brydon WG and Ferguson A: Lancet: 340 (1992) 1381-1382
HAZARDOUS SUBSTANCES AND NATURE OF HAZARD
CHEMICAL:
ethyl acetate: harmful-see COSSH form no 74
butanol: harmful - see COSHH form 20
oxalic acid: toxic - see COSSH form 187.
acetic acid:corrosive,flammable-see COSSH form no 138.
orthophosphoric acid: corrosive - see COSSH form no 40.
sodium azide: toxic - see COSSH form no 107
potassium ferricyanide : harmful - see COSSH form no 69.
potassium cyanide : toxic - see COSSH form no 68
BIOLOGICAL:
Both whole gut lavage fluid (WGLF) and faeces are potentially infectious and should be
handled appropriately. Procedures for cleaning glassware and disposal of tips which
have come in contact with these materials should be strictly adhered to.
PRECAUTIONS
Safety measures as detailed in the Departmental Safety Handbook must be followed.
Appropriate COSHH forms should be read and understood before undertaking this assay.
SPECIMEN REQUIREMENTS
1. WGLF: 2 x 1.5 ml samples of WGLF (unfiltered) should be aliquoted into 2 ml
microtubes with screw lids (Sarstedt, UK). 30 pi sodium azide (2 g/100 ml distilled
water) should be added as preservative, and samples stored at -70.
2. Random faecal samples (about 5 g) should be collected into universal
containers, and stored at -70.
SAMPLE STORAGE AND STABILITY
Samples of WGLF or faeces should be kept stored at -70, and analysed within 2 months. There
is no data on stability of samples beyond this time.
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INSTRUMENTATION
Fluorescence is measured using the LS-5B Luminescence Spectrometer (Department of
Medicine). Switch on main power (rear of instrument, rhs). Set excitation slit width to 15 nm
(Ihs), and emission slit width to 5 nm (rhs). Set excitation wavelength to 402 nm and emission
wavelength to 600 nm in the following way
1. Press low high reset simultaneously.
2. Press 402 goto EX
3. Press 600 goto EM
Leave instrument for 5 minutes to stabilise.
4. Place blank sample in cell carrier (nearest the instrument) and press
AUTOZERO (light on)
5. Place standard sample in the cell carrier set value eg 680 for 68.0 pg/ml
standard and press AUTOCONC (light on).
6. Repeat steps 4 and 5 to finalise calibration.
7. Test samples can now be read.
REAGENTS
All reagents are analar grade and obtained from Merck (BDH) unless otherwise stated. These
are stored in room 17.
1. Oxalic Acid Reagent: 4.0 g oxalic acid (analar) is made up to a 10 ml volume
with distilled water, and dissolved in a water bath at 100C. 0.31 g FeS04 is added to
the oxalic acid reagent which is returned to 100 C. 0.10 g uric acid and 0.11 g mannitol
are then added with mixing, final volume adjusted to 10 ml and the reagent left at 100 C
for 15 minutes. The reagent is prepared fresh before use and used as a suspension.
Dispose of excess reagent by washing down sink immediately after use.
2. Ethyl acetate/acetic acid 10/1 v/v. Add 50 ml glacial acetic acid to 500 ml ethyl
acetate in a fume cupboard. Mix and store in solvent cupboard. Label
corrosive/inflammable.
3. 3M Potassium Acetate (294 g/l). Dissolve 29.4 g potassium acetate (BDH
GPR) in 100 ml distilled water. Store at room temperature.
4. 3M Potassium Acetate in 1M Potassium Hydroxide (56 g/l). Dissolve 147 g
potassium acetate in about 300 ml distilled water, add 28 g potassium hydroxide (fume
cupboard), dissolve with stirring and make up to 500 ml with distilled water. Store at
room temperature. Label corrosive.
5. N-butanol (Rathburn Chemicals Ltd, Walkerburn). Store in solvent cupboard.
6. 2M H3P04/Acetic acid 9/1 v/v. Dissolve 68 ml orthophosphoric acid in 300 ml
distilled water (fume cupboard). When cool, make up to 500 ml with distilled water and
add 58 ml glacial acetic acid. Store in corrosives cupboard. Label corrosive.
7. PEG 4000 reagent: Dissolve 60 g PEG 3350, 9 g NaCI, and 0.2 g sodium azide
in 1 litre of distilled water. Use to make Drabkins reagent. Do not keep any excess
reagent. Flush down sink with copious water.
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8. Drabkins Reagent: (Sigma cat. no. 525-2) 6 vials.
Each vial contains 1 g sodium bicarbonate, 0.2 g potassium ferricyanide, and
0.05 g sodium cyanide.




Cyanomethaemoglobin Standard: Dissolve 10 mg haemoglobin (Sigma - H 7379) in 100 ml
Drabkins reagent. Leave at room temperature for 15 minutes. To calculate actual haemoglobin
concentration read OD at 540 nm against Drabkins reagent (blank).
Molar extinction coefficient (540 nm) = 44.0
Aliquot (0.5 ml) and store at -70. Label poisonous. Stable for up to 6 months.
QUALITY CONTROL MATERIAL
Take 10 mg haemoglobin (Sigma - H7379) and dissolve in 100 ml golytely. Add sodium azide to
final concentration 0.02 g/100ml. Aliquot (0.5 ml) into eppendorfs and store at -70° C. Label
toxic.
ANALYTICAL PROCEDURE
1. Lavage fluid samples should be frozen at -70°C before assay to allow
haemolysis of any intact red cells. After thawing these should be centrifuged at 2000
rpm in the Mistral 3000i (Room 1), and supernatant used for assay.
2. Add 0.4 ml of the oxalic acid reagent to 0.1 ml lavage fluid supernatant, quality
control, haemoglobin standard, and blank (golytely) in a 10 ml stoppered quickfit tube.
Mix thoroughly and heat at 100°C for 30 minutes in a water bath. Remove stoppers and
cool for 2 minutes.
3. Add 1 ml of the 3M potassium acetate reagent, followed by 3 ml ethyl
acetate/acetic acid reagent. Vortex mix for 30 seconds. This extracts the porphyrin
analytes into the upper organic phase.
4. Transfer 2 ml of the upper organic phase to a 30 ml stoppered quickfit tube and
add 0.8 ml butanol and 6.0 ml of 3M potassium acetate in 1M KOH. Mix for 30
seconds. This removes coproporphyrin and other porphrins not derived from
haemoglobin haem (contain more than 2 carboxyl groups) - extracted into the lower
alkaline aqueous phase.
5. Transfer 1 ml of the upper organic phase to a 10 ml stoppered quickfit
centrifuge tube, and add 3 ml phosphoric acid/acetic acid reagent. Mix for 30 seconds.
Remove the top layer which contains chlorophyll. Read the fluorescence of the lower
acid extract.
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6. For instructions in use of the spectrofluorometer see INSTRUMENTATION
section.
Tests readings /10 give results in pg/ml.
7. For faecal haemoglobin, weigh out about 0.1 g faeces, and add whole gut
lavage solution to this to make the final faecal concentration 0.1 g faeces per ml
lavage fluid. Break up the faeces into a fine suspension using wooden applicators and
rotaxixer. Use 0.1 ml faecal suspension (= 10 mg faeces) as sample and then analyse
as for lavage.
spectrofluorometer readings / 1000 give results in mg haemoglobin per g faeces.
NOTE Please retain all waste from extractions into a 500 ml reagent bottle and periodically
remove ethyl acetate/butanol upper phase to solvent waste bottle. Discard lower phase down
sink.
CALCULATION OF RESULTS
For WGLF test readings /10 give results in ug haemoglobin /ml WGLF.
For faeces test readings /1000 give results in mg haemoglobin /g faeces.
ACCEPTANCE OF RESULTS
The coefficient of variation (between batch - reproduceability) of quality control material
currently gives a value of 8%.
With a between batch variation of 8%, 2 SDs = 16% of mean value.
ie if mean value is 135 pg/ml, acceptable values will lie between 113 and 157 pg/ml. If the
value lies outwith this value the analytical run should be repeated.
REPORT FORMAT
The method for lavage haemoglobin is sensitive to 0.5 pg/ml, and results should be reported to
1 pg/ml.
For faecal haemoglobin results should be reported to 0.1 mg/g
Reference values for lavage haemoglobin range from 0-5 pg/ml.
(Brydon and Ferguson 1992).
Reference values for faecal haemoglobin range from 0.1 - 2.0 mg/g
CLINICAL SIGNIFICANCE OF RESULTS
The reference range for WGLF haemoglobin is 0-5 ug/ml which is equivalent to daily
blood loss of 1ml. Values in excess of this indicate pathological Gl blood loss.
The reference range for faecal haemoglobin is 0.1 - 2.0 mg/g faeces. Values in
excess of this indicate pathological Gl blood loss.
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INTERFERENCES AND LIMITATIONS
Other haem containing proteins have the potential to interfere in this assay; eg myoglobin in
meat, peroxidases in vegetables, although neither of these should cause significant interference
in lavage samples; lavage still contaminated with faecal material, where any blood cells may be
concentrated should be avoided. Faecal haemoglobin values can be raised by up to 1 mg/g
faeces for a daily red meat intake of 100 g, given an average stool output of 150 g. Vegetable




INSTRUCTIONS FOR USE OF LS-3B LUMINESCENCE SPECTROMETER
1. Switch on main power (rear of instrument, rhs).
2. Set excitation slit width to 15 nm (Ihs), and emission slit width to 5 nm (rhs).
3. Set excitation wavelength to 402 nm and emission wavelength to 600 nm in
the following way
1. Press low high reset simultaneously.
2. Press 402 goto EX
3. Press 600 goto EM
Leave instrument for 5 minutes to stabilise.
4. Place blank sample in cell carrier (nearest the instrument) and
press AUTOZERO (light on)
5. Place standard sample in the cell carrier set value eg 680 for 68.0
pg/ml standard and press AUTOCONC (light on).
6. Repeat steps 4 and 5 to finalise calibration.
7. Test samples can now be read.
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GAMMAVDELTA INTRA EPITHELIAL T CELLS IN SMALL INTESTINAL
BIOPSIES: QUANTIFICATION BY IMAGE ANALYSIS
TEST PRINCIPLE
Image analysis can be used to identify parameters such as size,number,shape,position and
optical density of identifiable parts of an image.
The Tas + image analyser utilises a microscope,video camera,visual display monitor,dec
computer with double disc drive and a printer.The computer software operates on the Tasic
programming language.
An image from the microscope is transferred by the video camera to the monitor.The image on
the screen is then altered to give an image suitable for measuring (image preprocessing),here
the image is converted into a binary image where different grey intensities can be detected.
The image analyser can now measure the areas that are detectable and record the value on the
printer.
REFERENCES
Leitz tasic + reference manual
Joyce-Loebl: Image analysis principles & practice
E.ARRANZ et al.Candidate markers of potential coeliac disease.unpublished data.
CHEMICALS AND EQUIPMENT REQUIRED
TAS + IMAGE ANALYSIS SYSTEM
fitted with good quality microscope *10 and *40 objectives.
Stage micrometer
SAMPLES
Cryostat sections that have been fixed in acetone and stained immunohistochemicaly using
monoclonal antibodies that detect CD3 or gamma delta expression.
INSTRUMENTATION
IMAGE ANALYSER
1 .Remove dust covers
2.Switch on at wall
3.Insert Tasic 8" floppy disk in drive 0 (left hand drive)
4.Insert G-l lab disc in drive 1
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5.Switch on with the key
6.Enter date on prompt,input the date followed by a dash,then the first 3 letters of the month
followed by a dash and then the last two digits of the year,eg 31-JUL-93.Press return.
7.Set up microscope
MICROSCOPY
For accurate quantification it is essential that the microscope is set to give optimum resolution
and even illumination.The best way to achieve this is by setting the microscope to give Kohler
Illumination.
A.Set lamp brightness on the control box to a comfortable intensity by pressing light switch
followed by the * button.
B.Divert the light to the microscope eyepieces,use the pull push rod at the top right hand side of
the microscope.
C.For *10 objectives and below remove flip top condenser.
D.Fully open the field diaphram (bottom of microscope).
E.Fully open the condenser diaphram (beside the flip top condenser)
F.Place a well stained section on microscope stage.
G.Focus on the section using the coarse focus knob,adjusting the focus in the eyepieces so that
both eyepieces are in equal focus.
H.Fully close the field diaphram.
I.Rack the condenser up and down until a sharp image of the field diaphram is obtained.
J.Centre the image with the centring screws on the condenser.
K.Open the field diaphram until it is just outside the field of view.
L.Remove the left eyepiece.
M.Close the condenser diaphram until it occupies one third of the light coming through the
eyepiece tube.
N.Repeat the set up procedure when changing to a new objective.
CALIBRATION OF IMAGE ANALYSER
Place stage micrometer on the microscope stage and focus. Switch light to video camera and
refocus using control box. Set focus on and use the arrow keys to focus up and down.
Line up the edge line of the box on the screen with the zero line of the stage micrometer,use
control box press stage button followed by arrow keys.The distance from one edge of the box to
the other can now be measured and the distance input into the image analyser for calibration.
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7.Set calibration by typing TSC148 if using *40 objective. For other objectives type in TSC




9.Type /E press return.
10.Type in the sample number on the prompt,press return.
11 .Select the field to be measured and then press return.
12.Turn up screen brightness and draw a line along the length of epithelium you wish to
measure.
13.Touch sensefield 20 with the light pen.
14.You should now touch your drawn line with the light pen.
15.The length of epithelium will now be printed on the screen.
16.On the screen the prompt will ask you to input the total number of +ve cells.Type in the
number of +ve cells in the epithelium of the area measured and press return.
17.The number of +ve cells will now be printed on the screen.
18.On the screen the prompt will ask you "do you wish another field yes or no?"
If you type y the new field number will be entered on the screen and you will be ask to select
new field (instruction 10).
If you type n the printer will print out the final measurements including the total number of
cells,the total area of lamina propria and the mean number of cells/sq.mm.
3
COUNTING PROCEDURE
The section is initially examined under a low power in order to assess its suitability for
counting.After initial examination the *40 objective is selected. Starting at one end of the
specimen the epithelium is followed along its length. Lengths of epithelium that are traumatised
are not measured or counted. A minimum of twenty fields should be counted.
REPORT FORMAT
The results are reported in whole numbers as the number of positive cells per mm.Only
specimens where the length of epithelium exceeds 3mm are reported except where discussion
with senior scientists and medical staff deem a lesser specimen reportable.
A senior member of the medical staff should place there comments on reports and an indication
of whether the result falls inside or outside the reference range noted.
The results of all counts are stored in printouts and recorded on the cryo floppy disk located in
room 20.Results include length of epithelium,cell numbers counted,% of gamma delta cells to
cd3 cells,pathology reports and biopsy numbers and diagnosis when available.
REFERENCE RANGE
The reference range for CD3 is < 68 per mm





CD3 LYMPHOCYTES IN SMALL INTESTINAL EPITHELIUM
TEST PRINCIPLE
CD3 + intra epithelial T lymphocytes are generally increased in patients with coeliac disease.
These cells can be detected by immunocytochemistry using the antibody monoclonal anti-CD3
on cryostat sections and quantified using image analysis.
Non specific antibody interaction is blocked by treating the section with diluted normal serum of
the host producing the secondary antibody. Monoclonal antibody directed against CD3 is placed
in contact with the tissue section and allowed to react.
The secondary biotinylated antibody which is directed against the bound monoclonal antibody
is then placed on the tissue section and allowed to react.
Finally the streptavidin biotin peroxidase is added and this binds to the biotinylated secondary
antibody.
The procedure is then visualised histochemicaly by reacting the peroxidase with the peroxidase
substrate diaminobenzidine.
The presence of endogenous peroxidase makes this method unsuitable for Lamina Propria
evaluation of +ve cells.The removal of peroxidase in the tissue section may be detrimental to
the demonstration of this particular antigen.
REFERENCES
J.SPENCER et al .Gamma/delta T cells and the diagnosis of coeliac disease. Clin
Exp.Immunology (1991) 85,109-113




Unfixed tissue is potentially infectious and should be handled appropriately.
CHEMICAL
Chemicals and serum should be handled in accordance with the appropriate COSHH forms.The
laboratory safety handbook procedures should be adhered to.
Cryospray Brights order code B1029; COSHH form no 155
Industrial Methylated Spirit (1MS99); COSHH form no 173
Acetone BDH analar grade product; COSHH form no 139
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Hydrogen Peroxide BP 6% (20 volume) Hilcross Pharmaceuticals ; COSHH form no 171.
3,3'-Diaminobenzidine Sigma COSHH form no 158.
Imidazole Sigma; COSHH form no 172
DePeX COSHH form no 157
Hematoxylin Gills N01 Sigma; code GHS-1-80; COSHH form no 169 :room 16
PATIENT PROCEDURE
see procedure for collection of jejunal biopsy.
SAMPLE COLLECTION , STORAGE, AND STABILITY
The monoclonal antibody is not suitable for specimens which have been processed to paraffin
wax.
Cryostat sections can be used following brief fixation in acetone.
Crosby capsule or endoscopic biopsies are collected unfixed as soon after biopsy as possible.
Tissue is placed in a drop of OCT on a glass slide and, under the dissecting microscope, is
orientated.
The villous surface should be uppermost and the tissue flat.
The tissue is then rapidly frozen,wrapped in tin foil and stored in the -70 freezer.
REAGENTS
SERUM AND ANTIBODIES
Rabbit serum SAPU;code S030-220 batch NO 6208T
room 16 fridge
monoclonal anti CD3 ;SAPU; cat NO TA 1061
room 16 fridge
Biotinylated Rabbit anti Mouse immunoglobulins Dako; room 16 fridge
StreptABComplex/peroxidase kit Dako code lot
room 16 fridge
OTHER REAGENTS
Poly-l-lysine 0.1%w/v Sigma code P 8920
Tris BDH analar code 10315
room 16





Pap pen Dako code 052002
room 16 Finpippete drawer
STOCK REAGENTS
0.01% Poly-l-lysine
Dilute Poly-I-lysine solution 1/10 with distilled water
store in fridge for up to 3 months.
0.5. Tris buffer pH 7.6
Dissolve 60.72gms of Tris in 500mls of Distilled Water adjust pH to 7.6 with 1N Hydrochloric
Acid and make up volume to 1ltr.
Store room 18 fridge
WORKING REAGENTS
1. 70% Industrial methylated spirit
IMS 70mls
Distilled water 30mls
2. 0.05M Tris buffered saline pH 7.6 (TBS)
dilute 0.5M tris buffer 1/10 with 0.9% sodium chloride
3. Normal Rabbit serum/TBS (NRS/TBS)(blocking serum)
Rabbit Serum : 1ml
TBS 0.05M pH 7.6 : 4mls
4. Antibody dilutions
a. anti CD3 1/20 in NRS/TBS(primary antibody)
b. Biotinylated Rabbit anti Mouse 1/300 in NRS/TBS(secondary antibody)




prepare at least 1/2 hr before use.
SUBSTRATE
3
1 0.5M tris pH 7.6 10mls
2 Diaminobenzidine 10mg
3 Imidazole 1 flake
4 6% Hydrogen peroxide 60ul
Prepare fresh
CONTROL SECTIONS
The lymphocytes in the lamina propria act as a +ve control.
ANALYSIS PROCEDURE
SECTIONING OF FROZEN TISSUE
The tissue is transferred to the cryostat - DO NOT ALLOW TO THAW - and bissected. Half of
the specimen is embedded at right angles in OCT and then frozen onto a cryostat specimen
holder.
6micron Sections are cut at a temperature of -15c TO -20c.The sections are placed on 0.01%
Poly-L-Lysine coated slides and allowed to dry at room temperature for 30 minutes to 4
hours.The slides are then wrapped in tin foil and stored in the -20C freezer.
FIXATION OF CRYOSTAT SECTIONS
Sections are removed from the freezer and allowed to rise to room temperature before removal
of tin foil.The sections should be thoroughly dry with no traces of moisture on the
slides.Sections can now be fixed in fresh analar Acetone for 30 minutes at room
temperature.After fixation sections are allowed to dry at room temperature for 30 minutes.A wax
pencil or a PAP pen can now be used to draw round the sections to form a reservoir for the
antibody solutions.
STAINING METHOD - CD3
1 Place sections in TBS pH 7.6
2 normal rabbit serum/TBS 1:4
3 drain but do not let section dry.
4 mouse monoclonal anti CD3 dilution 1/20 in TBS/NRS
5 rinse sections in a stream of TBS
6 wash in TBS
7 remove excess TBS but do not let sections dry
8 biotinylated rabbit anti mouse IgG dilution 1/400 in TBS/NRS
9 rinse sections in a stream of TBS
10 wash in TBS
11 remove excess TBS but do not let sections dry
12 streptavidin/biotin peroxidase complex in TBS
13 rinse sections in a stream of TBS
14 wash in TBS











16 wash in running tap water
17 stain in haematoxylin
18 wash in running tap water
19 saturated aqueous lithium carbonate till "blue'

















+ve cells,endogenous peroxidase brown
nuclei blue
the addition of 5% human serum to the secondary antibody can help be helpful in reducing non
specific background staining.
Cell counts and mucosal length measurment are carried out using the TAS+ Image Analyser.
Only +ve staining cells in the epithelial cells of the villi are counted and the length of mucosa
from the counted area measured.The measurements are carried out at *40 magnification using
the program CD3TCR.OCT.
REPORT FORMAT
The results are expressed as the number of +ve cells/mm of tissue.






ELISA = Enzyme linked immunosorbent assay
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TECHNIQUE PRINCIPLE AND METHOD OUTLINE
Non competitive ELISA assays are used to measure total or antigen specific
Immunoglobulins G, A or M in serum, lavage or aspirate materials. Antibodies commonly
measured those to gliadin (wheat protein), ovalbumin (egg protein) and lactoglobulin (milk
protein).
A double antibody sandwich technique is used for total immunoglobulin quantitation against
a purified secondary standard material. An indirect technique is used for estimation of
antigen specific immunoglobulins measured against a known high human sample.
Class specific antihuman immunoglobulin or pure food antigen is bound in excess to a solid
phase and then washed. In these methods, a 96 well ELISA plate is the solid phase -
different plate types have different binding characteristics.
The plates are incubated with a protein containing solution to "block" any non specific
binding sites.
Samples for total immunoglobulin quantitation are added to the plates in doubling dilutions -
in order to cover the wide range of concentrations found while samples for antigen specific
analysis are added at a single predetermined dilution. Samples are incubated and then
washed. Binding takes place between the antihuman globulin and the immunoglobulin being
quantified or between the specific antigen and corresponding antiantigen immunoglobulin.
A class specific antihuman antibody conjugated with alkaline phosphatase is added to the
plate, incubated and then washed. This conjugated antibody binds to the complex bound to
the solid phase.
The substrate for alkaline phosphatase is p-nitrophenyl phosphate in a diethanolamine uffer
at pH 9.8. The substrate is added to the plate and the reaction
p-nitrophenyl phosphate p-nitrophenol
colourless yellow
takes place. The colour development takes place within an hour and the optical density at
405 nm is read on a dedicated spectrophotometer/ELISA reader, a Dynatech MR5000. The
colour development can be monitored and the absorbances measured when the top
standard or reference standard has reached a previously determined value.





SPS-01 - standard material for quantifying IgG and IgM. Purchased in 5 x 1 ml vials from
Dept. of Immunology, P O Box 894, Sheffield S5 7YT.
Store at 4 °C in fridge A. Date bottle on opening and discard after 1 month.
Current batch
Total IgG cone g/l
Required top std for IgG assay in lavage is 250 ng/ml
Dilute 10jo.1 SPS-01 in pi diluent to give cone 100 pg/ml
Dilute 1Opl diluted SPS-01 (100pg/ml) to 4 ml to give cone 250 ng/ml
Total IgM cone g/l
Required top std for IgM assay in aspirate is 1000ng/ml
Dilute 10 pi SPS-01 in ml to give cone 1000 ng/ml
Human IgA - purified immunoglobulin from colostrum. Standard material for quantifying
IgA in secretions. Purchased in 1 ml vial from Sigma Chemical Co., Cat No I-2636
Current batch
Total IgA cone g/l
1 ml cone (neat) soln diluted to 10 ml to give cone pg/mi
110 pi aliquots at pg/ml stored at-20°C in freezer B
Required top std for IgA assay in aspirate = 1000ng/ml
Dilute 100 pi fresh aliquot in ml to give cone 1000 ng/ml
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ELISA REAGENTS (1 cont)
Coating antibodies
Goat antihuman IgG, Fc specific, Affinity purified, purchased from Sigma Chemical Co. (Cat
No 12136)
Current batch Use at 1 : dilution
Goat antihuman IgM, p. chain specific, purchased from Sigma Chemical Co. (Cat No I2386)
Current batch Use at 1 : dilution
Goat antihuman IgA, a chain specific, purchased from Sigma Chemical Co (Cat No 12261)
Current batch Use at 1 : dilution
Conjugated antibodies
Goat antihuman IgG, alk phos conjugated, purchased from Sigma Chemical Co (Cat No
A9544)
Current batch
For Antigliadin ELISA Use at 1: dilution
For Total IgG ELISA Use at 1: dilution
Goat antihuman IgM, alk phos conjugated, purchased from Sigma Chemical Co (Cat No
A3437)
Current batch
For Total IgM ELISA Use at 1: dilution
Goat antihuman IgA, alk phos conjugated, purchased from Sigma Chemical Co (Cat No
A3036)
Current batch
For Antigliadin ELISA Use at 1: dilution
For Total IgA ELISA Use at 1: dilution
4
ELISA REAGENTS (2)
All solutions must be dated and signed.
Sterile Water
1 litre sterile water containers (Baxter Healthcare Code F7114) are stored at 4°C in the
cold room.
Coating buffer
Carbonate-bicarbonate coating buffer, 0.05M, pH 9.6 at 25°C. Dissolve the contents of 10
capsules (Sigma Chemical Co. Cat No C-3041) in 1 litre sterile water. Mix to dissolve and
store at 4°C in fridge A.
Sodium chloride
0.9% sodium chloride in 1 litre sterile containers (Baxter Healthcare Code F7124) is stored
at 4°C in the cold room.
Wash Solution
0.9% saline + 0.05% Tween 20 is the wash solution used for both manual washing of ELISA
plates and for the Dynatech MRW ELISA automatic washer.
Add 500 (j.l Tween 20 (Polyoxyethylene-Sorbitan Monolaurate, Sigma Chem Co. Cat No P-
1379) to 1 litre of 0.9% saline. Mix and store at 4°C in fridge A.
Adult Bovine Serum
Adult bovine serum is purchased from SAPU, Law Hospital, Carluke, Lanarkshire, ML8 5ES
(Product No S026-220) in 20 x 20 ml aliquots and kept frozen at - 20°C in Freezer B. Allow
an aliquot to reach room temperature and then filter through a 22u filter before using to
constitute the Diluent. The second 10 ml of the aliquot can be stored at 4°C in Fridge A for
1 week before use.
Diluent
0.9% saline + 0.05% Tween 20 + 1% adult bovine serum.
Add 500 pi Tween 20 and 10 ml filtered adult bovine serum to 1 litre of saline. Mix and
store at 4°C in fridge A.
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ELISA REAGENTS (2 cont)
Diethanolamine (DEA) substrate
5 litres of DEA substrate is constituted in a semi quantitative flask.
Add:
500 ml diethanolamine - concentrated liquid (purchase 4 x 500 ml from BDH Laboratory
Supplies, Poole, BH15 1TD. Analar Reagent Product No 10393 4J) stored in the flammable
cupboard at room temperature in the chemical store.
0.51 g magnesium chloride (Mg CI26H20)
1.0 g sodium azide (NaN3)
4 I sterile water
Adjust the pH to 9.8 with 6N hydrochloric acid (HCI) - kept in Room 1 Chemical cupboard
and make up to 5 I with sterile water.
Store in 1 litre bottles (ex sterile water) at 4°C, 1 currently in use in Fridge A and the
remainder in the Cold Room.
P-nitrophenylphosphate
5 mg phosphatase substrate tablets - disodium p-nitrophenyl phosphate hexahydrate.
Purchase 8 x 200 tablet bottles from Sigma Chemical Co Product no 104-105. Tablets are
stored at -20°C in freezer B.
Alkaline phosphatase substrate
Fresh substrate is constituted aprox 30 mins before required. Dissolve 1 tablet phosphatase




The ELISA plate washer is programmed for several (usually 3) wash cycles followed by an
optional fill with blocking solution.
The instructions for the use of this instrument are on the adjacent wall and in the Room 13
Equipment Folder. Instructions must be followed carefully with particular attention paid to
decontamination procedures.
Denley Wellmixxl
The Wellmix can shake 1 or 2 ELISA plates automatically.
It is switched on at the wall socket and by rocker switch at the front of the shaker.
Dynatech MR5000 Microplate Reader
The microplate reader is used in the MANUAL mode in order to find the current absorbance
of samples and in this mode is used to determine the end point of the alkaline phosphatase
development reaction.
The microplate reader is also used in a programme mode - set at the appropriate
programme for the analysis being carried out - to measure the final absorbance and if
required to use the absorbances to calculate the results of the assay.
The instrument is programmed via the touch sensitive front panel.
1. Switch on the microplate reader (power switch at back of instrument) and attached
printer. The instrument runs a self check (about 10 s) then shows READY.
2. Place plate on the plate carrier.
3. Press MANUAL
4. Wavelength mode ? Press DUAL
5. Filter - set to 405nm, ENTER
6. Ref. Filter - set to 630 nm, ENTER
7. The instrument will now read the absorbances of the plate and hold the results so that
the absorbance at each plate position can be viewed by using the directional arrows.
8. When the (top) standard has reached the required value read the plate on the
corresponding test programme.
9. Press START
10. Test number = Enter programme no. ENTER to confirm correct assay programme.
11. Plate = using direction arrows and/or number keyboard enter any combinations of
letters or numbers to identify the plate.
12. The absorbances will now be read and printed out in template pattern.
13. If only absorbances are required ESC.




The Departmental Safety Handbook and the relevant COSSH forms must be read before
undertaking any assay.
Chemical hazards:
1. Diethanolamine (DEA): toxic, irritant - see COSSH form # 70
2. P-nitrophenylphosphate tablets: harmful - see COSSH form # 76
Biological hazards
All patient material, and standard or control material of animal origin, must be regarded as
potentially infectious and handled accordingly. Manually washing of plates containing
biological material must be by vacuum into a sealed waste trap. Biological waste from
manual washing or using the Multi-Reagent Washer must be decontaminated using Presept
tablets before discarding down the sink.The disposal of tips and tubes must be as
recommended in the laboratory safety handbook.
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ESTIMATION OF ANTIGLIADIN IqA AND IqG IN SERUM
TEST INDICATIONS
Serum IgA and IgG antigliadin antibodies (AGA) are measured in patients to support a
diagnosis of coeliac disease and in patients in whom this diagnosis has been confirmed to
follow the compliance of a gluten free diet.
TEST CONTRAINDICATIONS
Serum IgA and IgG AGAs are not helpful in diagnosis if the patient is already on a gluten
free diet.
Serum IgA AGA is not indicated in patients with IgA deficiency and in cases with
inappropriately low levels of serum IgA AGA a general IgA deficiency should be considered.
TEST PRINCIPLE
Serum IgA and IgG AGA concentrations are routinely measured against a precalibrated
human serum in a dilution series using an ELISA technique.
REFERENCES
Unsworth D.J., Leonard J.N., McMinn R.M.H., et al. Br. J. Dermatol. 1981 105 653-8
Anti-gliadin antibodies and small intestinalmucosal damage in dermatitis herpetiformis.
O'Mahoney S., Arranz E., Barton J.R., Ferguson,A. Gut 1991 32 29-35
Dissociation between systemic and mucosal immune resposes in coeliac disease.
PATIENT PROCEDURE
There are no specific conditions pertaining to the collection of blood samples for this assay.
Details of the patient's diet should be obtained.
SAMPLE STORAGE AND STABILITY
10 mis blood are drawn from a patient using a monovette (z/10) and needle and allowed to
clot at room temperature for 1 hour.
The blood sample is centrifuged at 2500 rpm for 10 minutes then the serum separated into
storage tube(s) following sample processing procedures. (Refer to Protocols File)
Samples are stored at -20°C in the freezer in Room 1.
Serum or plasma can be used in this assay. (Refer to Method Development file for validation
of the use ofplasma)
Samples are stable for up to 1 year if stored as above.
STANDARD AND QUALITY CONTROL MATERIAL
A patient who is expected to have raised serum AGA levels is asked to give consent to have
a large blood sample taken and tested for Hepatitis and HIV infectivity. A 50 ml blood
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sample is taken, separated, an aliquot is sent for testing and the remaining serum stored at
-20°C. If this sample is negative for infectivity and the AGA value is appropriate the sample
is calibrated against the current standard or control material and then divided into 1 OOjj.1
aliquots in small Eppendorf tubes and stored at -70°C in Freezer 2.
Two QC material are used, 1 within the reference range (Lo QC) and 1 above the reference
range (Hi QC). A Lo QC can be produced from a sample with a high level by dilution with a
tested sample of very low level. New QC material must be run in parallel with current to
establish confidence limits.
(Refer to QC documentation in the Protocol file for details of the current materials used)
ANALYSIS PROCEDURE
1. Coat plate with appropriate GLIADIN solution. Use IMMULON 2, flat bottomed, gamma
irradiated plates for these assays. Prepare a template to mark the sample positions.
GLIADIN - gliadin extract (Sigma G-3375) is stored at room temperature in Room 13.
Weigh out 5mg antigen and dissolve in 10 ml Coating Buffer using a magnetic stirrer to
give 0.5 mg/ml solution. Further dilute 1 ml of this stock in 20 ml of coating buffer to
give a coating solution of 25 pg/ml.
2. Using an 8 channel multichannel pipette, dispense 100 p.1 coating solution to each well
of the ELISA plate.Cover plate with a plastic lid, place in a moist box and incubate at
22°C for 5 hours.
3. Block plate
Either manually or using the Dynatech M-RW wash the plate x 3 with wash solution, and
then add 250 pi Diluent. Replace plate in moist box at 22°C and leave for a minimum of
2 hours.
4. At this stage the plate may be vacuum sealed into a plastic bag and stored at -20°C
until required. Several plates can therefore be prepared at the same time, stored, taken
out individually as required. Plates stored in this manner are stable for at least 3
months. Allow to reach room temperature before proceeding to the next stage.
5. Prepare standards
IgA - dilute standard material in Diluent - currently = Main @ 1/100 (add 10pl standard
to 990pl Diluent), next = sample 95/1548 @ 1/467 (add 3pl standard to 1398pl Diluent).
IgG - dilute standard material in Diluent - currently = Main @ 1/250 (add 4pl standard to
996pl Diluent), next = sample 95/1548 @ 1/1115 ( add 3pl standard to 3342pl Diluent).
6. Prepare samples
IgA - dilute QC samples and test samples 1/1000 in Diluent (add 3pl sample to 2997pl
Diluent).
IgG - dilute QC samples and test samples 1/2000 in Diluent (add 2.5pl sample to
4997.5pl Diluent) or alternatively further dilute the sample dilution for IgA 1/2 in the
plate (add 50pl 1/1000 sample to 50pl Diluent in each well).
7. Load standards, QC material and sera on to the plate
Dispel the blocking solution from the plate and blot dry on absorbant paper.
Using the 8 channel multipipette, dispense 100pl Diluent into wells A1, A2, and C1 &2 to
H1&2.
To B1, B2, C1 and C2 add 10OpI of the appropriate standard. Mix the standard and
diluent in C1, C2 by drawing up and down the pipette tip 3 times. Transfer 100pl to D1,
D2, mix, and so on down the plate to prepare a doubling dilution series.
Load 100pl of QC samples and serum samples into duplicate wells as planned on the
template.
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8. Cover plate with a plastic lid and incubate the plate at 4°C overnight in a covered moist
box.
9. Conjugate
Prepare alk.phos conjugated antisera dilutions in Diluent following dilutions on page 4.
10. Wash plate as above, then using an 8 channel multipipette dispense 100 jot of the
appropriate conjugate to each well of the ELISA plate.
11. Cover plate with a plastic lid, place in a moist box and leave at 22°C for 5 hours.
12. Colour Development
Prepare alkaline phosphatase substrate (15 mis per plate) no more than 15 mins before
it is required.
13. Wash plate as above, then using an 8 channel multipipette dispense 100 |il substrate to
each well of the ELISA plate. Leave on the bench as the colour starts to develop and
only shake on Wellmix if colour development is very slow.
14. Monitor the colour development manually on the Microplate Reader and as the
appropriate standard reaches its endpoint START the programme.
Absorbance endpoint for IgA = when top standard reads about 1.00
Absorbance endpoint for IgG = when 2nd standard reads about 1.00
15. Programme for antigliadin assay = 43 "GLIADIN". The printout automatically subtracts
the blank value (A1 and A2).
CALCULATION OF RESULTS
Plot the duplicate standard absorbance values as y co-ordinates on Inplot or Prism graph
programmes, using the following values as x co-ordinates:
IgA top standard = 1.0 Handy Units, 2nd standard = 0.5 etc
IgG top standard = 0.8 Handy Units, 2nd standard = 0.4 etc
Plot the best curve fit through these points using non-linear regression.
Mean the duplicate absorbance values for each QC and test.
Using the appropriate command, calculate the corresponding results in Handy units from the
standard curve for all the QC and test absorbances, remembering to multiply the result read
off the curve by the appropriate dilution factor (e.g. 1000 for IgA).
ACCEPTANCE OF RESULTS
The test results are technically acceptable if the QC absorbance values lie within 95% of the
current QC absorbance values and if the duplicate values differ by no more than 10%.
REPORT FORMAT
Results are entered into the REPORTS database reported to the nearest whole number, and
printed via the Mailmerge programme.
Serum antigliadin IgA = units
(Reference range 0 - 30 units)
Serum antigliadin IgG = units
(Reference range 0 - 45 units)
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CLINICAL SIGNIFICANCE OF RESULTS
Results are assessed in conjunction with IgA antiendomysium antibody results.
Serum IgG AGA levels increase with age and a single raised IgG AGA result is not usually
clinically significant.
Since a definitive diagnosis is still dependent upon a histological assessment, if IgA and IgG




Within batch CV = 9.4% at 20 units
= 7.5% at 90 units
Between batch CV = % at units
= % at units
Antigliadin IgG
Within batch CV = 9.9% at 26 units
= 5.9% at 117 units
Between batch CV = % at units
= % at units
STANDARDISATION
When a new standard serum is required the next sample from a likely patient (see Standard
and Quality Control Material section) should be run on the assay several times to ascertain
the sample's unitage. The potential standard should then be run in a doubling dilution series,
starting with dilutions which should give a result of 1.0 units for IgA or 0.8 units for IgG,
alongside the current standard curve. 3 such curves should be run using starting dilutions
around the calculated value, and the curves plotted on top of the current standard curve.
The set of dilutions which best fits the current standard curve should be chosen. If none is a
good fit then the excercise should be repeated with different starting dilutions, according to
which way out the curves were.
For example:
IgA - Main - top standard of curve (1/100 dilution) = 1.0 units.
95/1548 was run several times giving an average result of 471 Handy units in the serum.
Thus a dilution of 1/471 of the serum should produce a solution containing 1.0 units to be
used as the top standard. In practise 1/467 was actually used.
So 95/1548 was run in dilution series starting with 1/400, 1/467 and 1/500 as the first
dilutions. These were run alongside Main standard curve. The 1/467 curve fitted exactly
over the Main curve, and furthermore samples which were read off from both curves gave
almost identical results at high and low levels.
IgG - top standard = 0.8 units, therefore a sample with 892 units in would need a 1/1115
dilution to produce a solution containing 0.8 units. So this plus two other dilutions (e.g.
1/1050 and 1/1200) should be compared with the original curve.
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ESTIMATION OF TOTAL IqG IN LAVAGE
TEST INDICATIONS
Patients may undergo bowel cleansing prior to endoscopic procedures or surgery or at the
start of an elemental diet. The whole gut perfusate (WGL) obtained after the removal of all
faecal material contains any biochemical compounds which have been secreted or leaked
into the gut. The concentration of total lgG (and also albumin and a1-antitrypsin) in WGL
fluid are raised in patients with active gut inflammation.
Total IgG is therefore measured in WGL to assist in the diagnosis of inflammatory bowel
disease and in patients with confirmed disease as an alternative/additional measure of the
degree of inflammation.
TEST CONTRAINDICATIONS
Bowel preparation using WGL fluid may not be appropriate in all patients.
The measurement of proteins in WGL fluid is only useful if the WGL has been strictly
collected and treated according to the protocols.
TEST PRINCIPLES
Total IgG in lavage is quantified against the protein reference standard (SPS-01).in doubling
dilutions using an Elisa technique.
REFERENCES
Gaspari M.M., Brennan P.T., Soloman S.M. Elson.C.O. J. Immunol. Methods 1988 110 85-
91 A method of obtaining, processing and analysing human intestinal secretions for
antibody content.
O'Mahoney S., Choudari C.P., Barton J.R., Walker S., Ferguson A. Scand.J. Gastroenterol.
1991 26 940-944 Gut lavage fluid proteins as markers of activity in inflammatory bowel
disease.
PATIENT PROCEDURE
Hospital inpatients or outpatients must present for bowel preparation fasting.
Patients are required to drink aproximately 4 litres of Klean-Prep -a polyethylene glycol
electrolyte solution- at a rate of 1 glass (250 mis) every 10 minutes. Alternatively the liquid
may be given via a naso-gastric tube.
After aproximately 2 hours the patient passes loose watery stools which, on continued
drinking, becomes a clear yellow liquid. When the rate of influx is standardised , this
becomes essentially a gut perfusate. 60 mis of this clear fluid is collected for processing.
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SAMPLE STORAGE AND STABILITY
IgG in untreated lavage material is stable for 2 hours at 37°C However since the material is
usually required for the estimation of other more labile parameters it must be processed and
stored immediately after collection.
Samples are processed as directed in the lavage processing protocol and stored at -70°C.
The processing required and the volumes stored may vary depending upon the current
requirements. Aliquots of the same sample are stored in both -70°C freezers for "insurance
purposes".
The sample required for total IgG estimation is filtered and fully processed. This sample is
stable at -70°C for 3 months.
STANDARD MATERIAL
Protein reference standard SPS-01 is diluted in Diluent as detailed on page 4.
QUALITY CONTROL MATERIAL
A patient who is suspected of having raised inflammatory parameters is asked to give
consent to have his sample tested for Hepatitis B and HIV infectivity. A large volume is
stored at -70°C. If this sample is negative and the values are appropriate, the frozen
material is thawed, filtered, processed and aliquoted into 500pl aliquots and frozen at
-70°C. If the IgG level is inappropriately high then it can be diluted with "Klean-Prep".
Ideal values for the QC material are at the upper limit of the reference range.
(Refer to QC documentation in the Protocolfile for details of the current materials used)
ANALYSIS PROCEDURE
1. Coat plate with appropriate antigen
Use Immulon 1 flat bottomed plates. Prepare a template of the sample positions.
Dilute IgG coating antisera in carbonate/bicarbonate coating buffer pH 9.6 as detailed
on page 4.
2. Using an 8 channel multichannel pipette, dispense 125 pi coating solution to each well
of the Elisa plate .Cover plate with a plastic lid, place in a moist box and incubate at 4°C
overnight.
3. Block Plate
Either manually or using the Dynatech M-RW wash the plate x 3 and then add 250 pi
Diluent. Leave for a minimum of 1 hour.
4. Prepare samples
Dilute the standard material as detailed on page 3
Allow lavage samples and QC material to reach room temperature.
Dilute the samples and QC material 1/25 in Diluent (add 40pl sample or QC material to
960pl Diluent)
5. Add samples to the plate
Dispel the blocking solution from the plate and blot dry on absorbant paper
Using the 8 channel multipipette add 125pl of diluent to all wells except for B1 ,B2 and
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A3-A12
To B1 ,B2 and C1 ,C2 add 125pl of the appropriately diluted standard. Mix the standard
solution and the diluent in C1 ,C2 by drawing up and down the pippette tip 3 times.
Then,transfer 125pl from C1 ,C2 to D1 ,D2 and so on to produce a series of doubling
dilutions.
Similarly, after vortex mixing the diluted lavage samples, add 125pl to duplicate colums
(eg.A3,A4 and B3,B4). Then by mixing the sample and diluent in B3, B4, produce
doubling dilutions of the samples.
6. Cover plates with a plastic lid and incubate overnight at 4 °C in a covered moist box.
7. Conjugate
Dilute the alkaline phosphatase conjugated antisera as detailed on page 4.
8. Wash the plates as above.
9. Add 125 pi of conjugate to each well using the 8 channel multipipette.
10. Cover the plate with a plastic lid and leave in the corridor incubator at 24°C for 3 hours.
11. Colour Development
Prepare alkaline phosphatase substrate (15 mis per plate) 30 mins before it is required.
12. Wash the plates as above.
13. Add 125pl of prepared substrate to each well using an 8 channel mutipipette. .Leave the
plates on the bench for 5mins as the colour starts to develop, then shake on the
Wellmixx.
14. Monitor the colour development manually on the Microplate Reader and as the top
standard nears its endpoint START the programme.
Absorbance endpoint for IgG = 1.0
15. Programme for total IgG = 11. This programme will automatically subtract the blank
absorbance values (wells A1.A2) from all wells.
CALCULATION OF RESULTS
Results can be calculated using a pocket calculator with statistical programmes, using the
software programme on the Dynatech Microplate Reader or using the Minitab statistical
package on the lab p.c.
The following method uses the first of these options.
Draw out a standard curve of absorbance readings against concentration of immunoglobulin
at each dilution of the standard. Using the linear portion of the curve, calculate the linear
regression line for these standards. Check the correlation coefficient.
Using the linear regression equation calculate the concentration of the QC and each sample
at several dilutions
ACCEPTANCE OF RESULTS
The correlation coefficient for the standard curve must be greater than 0.985.
Sample results from plates on which the QC value falls within 95% of the current QC
mean value can be accepted for reporting.
Samples must have 2 or more points parallel to the standard curve and a mean of the
concentrations at these parallel points is taken as the result.
Samples with absorbances above those of the standard curve are repeated at a starting
dilution of 1/250 ( add 4 pi lavage to 996pl Diluent)
REPORT FORMAT
Results for lavage total IgG are entered into the REPORTS database, reported to the
nearest whole number. Samples with very high results that have required dilution are
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reported to the nearest 10. The results are reported as one of the "inflammatory bowel
assessement / blood loss" parameters and printed using the mailmerge programme.
Lavage total IgG reference range 0-1 Opg/ml
CLINICAL SIGNIFICANCE OF RESULTS
Total IgG is the most sensitive parameter to inflammation in the gut. The relevent comment
is
"Results indicate active inflammation".
METHOD VALIDATION
Performance characteristics
Lavage total IgG : Between batch CV =12.3% at 19.8p.g/mli
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